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Plan of thesis 
 
This thesis consists of five chapters.  
 
Chapter One is a general background into Lynch syndrome, its molecular 
pathology and extracolonic manifestations. The aims and objectives of this thesis 
are also provided.  
 
Chapters Two, Three and Four are the experimental chapters. Chapter Two 
investigates the contribution of a polymorphism in the hMLH1 gene to the 
extracolonic cancer spectrum of Lynch syndrome in a large cohort. Chapter Three 
centres on the search for a uniform genetic signature between Lynch-associated 
malignancies. A panel of genes was assessed as well as Multiplex Ligation 
dependant Probe Amplification (MLPA) in a cohort consisting of germline DNA and 
their tumour DNA counterparts. Chapter Four focuses on the bioinformatics 
analyses of existing microarray data to supplement the study.  
 
Finally Chapter Five provides an overview of the project and includes potential 













Lynch Syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC) (OMIM #120435), is a familial disorder resulting from mutations within 
DNA MMR genes.  Effective surveillance, diagnosis and treatment of the disorder 
is complicated due to the phenotypic and genetic heterogeneity of lynch 
syndrome, which exhibits an autosomal dominant mode of inheritance.  
 
Aim: Determine the molecular pathology of extracolonic cancers in Lynch 
syndrome and to elucidate whether or not the occurrence of these extracolonic 
cancers are a direct result of the mismatch repair deficiency. 
 
 Materials and Methods: First, a modifier study was performed assessing the 
effect of a variant within the DNA MMR gene hMLH1 in a cohort of individuals 
predisposed to Lynch syndrome in order to examine a potential epistatic effect in 
the gene. In order to obtain a genetic signature of Lynch associated tumours, 
germline DNA and corresponding tumour DNA was isolated from Lynch syndrome 
patients. The genetic material was assessed via a panel of microsatellite rich 
genes and MS-MLPA. Finally, in silico analyses were undertaken assessing 
microarray data from microsatellite unstable colorectal and endometrial cancers to 
characterise novel candidate genes.  
 
Results: The modifier study did not prove fruitful as no association was found 
between the hMLH1 promoter variant and site of cancer in individuals predisposed 
to Lynch syndrome. An association was observed heterozygous and homozygous 
variant genotypes and an increased risk of colorectal cancer, regardless of 
predisposing mutation (p = 0.000181). Two tumour suppressor genes; HIC1 and 
TIMP3, were found to be methylated in the tumour samples in the germline/ 











majority of tumour samples. Bioinformatic analysis utilising existing microarray 
data resulted in common under-expression of four genes and common over-
expression in three genes in microsatellite unstable colorectal and endometrial 
cancers.  
 
Conclusion: Further investigation into the modifier study and elucidation of a 
genetic signature in MMR deficient, MSI cancers. The results obtained in this 
study contribute to the increasing body of knowledge in the field and the various 
stages of malignancies should be assessed for a more informative result. Genetic 
and functional studies should be performed on the information garnered from the 
bioinformatics analysis. Overall evaluation and molecular classification of Lynch 
syndrome tumours may guide better diagnosis, surveillance and treatment of 













1.1. Lynch Syndrome 
 
Lynch Syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC) (OMIM #120435), is a familial disorder. It exhibits an autosomal 
dominant mode of inheritance and a penetrance of about 80% (Lynch and De La 
Chapelle 2003). As a result, multiple generations are affected with synchronous 
and metachronous, colorectal and extracolonic cancers (Douglas et al.  2005).  
Although the incidence of Lynch Syndrome in South Africa is unknown, it is likely 
to match the international figures which are reported to account for 2 – 5 % of all 
colorectal cancers (Lynch and De La Chapelle 2003, Cancer Research 2006).  
 
While it is imperative to identify families with Lynch Syndrome (via presymptomatic 
genetic testing), management and surveillance of the disease is costly, invasive 
and not always accessible particularly in a resource-poor country.  The disease 
could be detected early and life may subsequently be prolonged with rigorous 
screening of predisposed individuals. In a developing country, provision of the 
medical centres required for adequate screening and management procedures are 
not feasible. A recent study has shown that annual screening for these 
malignancies allows for a longer cancer-free lifespan and onset of severe disease, 
which can be more successfully treated and managed by preventing its escalation 
(Lynch and De La Chapelle 2003).   
 
1.2. History of Lynch Syndrome  
 
In 1913, Dr Albert Scott Warthin first described a family with numerous 











2005). Dr Henry T. Lynch, in 1966, further investigated and expanded on the initial 
diagnosis made by Dr Warthin (Lynch and Lynch 1997).  
 
To further investigate the disease, an International Collaborative Group for the 
study of HNPCC (ICG-HNPCC) was formed in 1989 under the leadership of Dr 
Lynch.  In 1990, part of the mandate of the ICG-HNPCC was to identify criteria 
through which diagnosis of Lynch syndrome could be made (ICG-HNPCC 2004). 
Known as the Amsterdam criteria, it was originally based on a detailed family 
history. The criteria subsequently evolved in order to incorporate the inclusion of 
extracolonic cancers found within the HNPCC tumour spectrum (Table 1) (Lynch 
et al.  2003).  
 




1. At least three relatives with colorectal cancer, one of whom is a first degree relative of the 
others 
2. Colorectal cancer involved at least two generations 
3. One or more of the colorectal cancers presented before the age of 50 years (y) 
Modified Amsterdam Criteria 
1. At least three relatives diagnosed with Lynch-associated cancers (colorectal, 
endometrial, small bowel, ureter or renal pelvis cancer); one of whom is a first degree 
relative of the other two 
2. Colorectal cancer involving two generations   
3. One or more of the colorectal cancers presented before the age of 50y 
 
These criteria resulted in the identification of large families with Lynch syndrome. It 
is unfortunately recognised that due to the stringency of the Amsterdam criteria, all 
families affected with Lynch syndrome may not be acknowledged. Subsequently 
further studies have found families who do not adhere to the previously defined 
criteria (Table 1) yet have been shown to carry mutations in genes, known to be 











arises as the families present with later ages of onset and variable penetrance of 
the disease (Fearnhead et al.  2002; Lynch and Lynch 2000; Gonzalez-Aguilera et 
al.  2003).  
 
1.3. Genetic Basis of Lynch Syndrome  
 
Mutations within the DNA Mismatch Repair (MMR) genes, which encode DNA 
MMR enzymes, are responsible for Lynch Syndrome. Collectively, the DNA MMR 
enzymes form the DNA MMR system which ensures the fidelity and integrity of the 
DNA sequence during DNA replication. This regulatory system scans the genome 
for mismatches, insertions and deletions during DNA replication and repairs any 
errors (Watson et al.  2004, Peltomaki 2005).  
 
1.3.1. DNA MMR system  
 
In 1975, DNA mismatch repair genes were first discovered and characterised in 
the bacterium, Escherichia coli. Between 1988 and 1991, human mismatch repair 
activity was demonstrated (Lynch and Lynch 1997) and the first DNA MMR gene 
was described in 1993 (Peltomaki et al. 1993). The human DNA mismatch repair 
genes are named after their bacterial homologs (Snustad and Simmons 2003).  
 
The simplest DNA MMR system is found in prokaryotes and consists of a MutS 
protein, which scans replicating DNA for errors and a MutL protein, which 
facilitates the repair of errors (Jun et al.  2006; Marti et al.  2002). In contrast, 
higher organisms have several MutS (referred to as MSH) and MutL (referred to 
as MLH) homologs. For accurate functioning of the system, the DNA MMR 











(Chao and Lipkin 2006). The system is adenine triphosphate (ATP) dependant and 
the ATP binding sites on each protein are highly conserved in eukaryotes. 
Comprehensive reviews on this system are available (Kunkel and Erie 2005; Jun 
et al.  2006; Schofield and Hsieh 2003; Marti et al.  2002).  
 
The function of the DNA MMR system in humans is schematically represented in 
Figure 1 below. A MSH protein, MSH2, comes into contact with newly synthesized 
double-stranded DNA and scans it for mismatches. Once an anomaly is 
encountered, MSH2 recruits and binds to the appropriate MSH MMR protein in 
order to rectify the defect. If the mismatch is a single base-pair substitution or a 
one base-pair insertion or deletion in the DNA sequence, the MSH2 protein 
recruits the MSH6 protein. For insertions or deletions in the sequence from one to 
four base-pairs in length, MSH2 recruits an MSH3 protein. Thereafter, the primary 
MutL complex, a heterodimer consisting of the proteins MLH1 and PMS2, 
recognizes the MutS complex and binds to it and catalyses the repair of the DNA 
(Chao and Lipkin 2006). Additional factors, (EXO1, PCNA and MED1), essential 
for effective repair of the DNA are recruited. However, if the DNA damage is too 
extensive and unable to be effectively repaired, the DNA MMR system induces the 
cell to undergo apoptosis via the p73 apoptotic pathway (Marti et al.  2002; Jacob 
and Praz 2002). MLH1 and PMS1 proteins also form a MutL complex however, the 
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Figure 1:  Schematic representation of the function of the human DNA MMR   system. 
Information obtained from Kunkel and Erie 2005; Jun et al.  2006; Schofield 












1.3.2 Defects in the MMR system  
 
Mutations within DNA MMR genes predispose to a cancerous phenotype. The 
DNA MMR genes act as tumour suppressor genes and require both copies of the 
gene to be inactive to allow for initiation of malignancy (Chao and Lipkin 2006). 
Genetic heterogeneity is evident as a mutation in any one of the mismatch repair 
genes can result in the same phenotypic outcome.  
 
1.3.2.1. Monoallelic Germline Mutations 
 
A monoallelic germline mutation in a DNA MMR gene predisposes to Lynch 
Syndrome. Loss of the second allele, leads to the lack of expression or a defective 
protein, consequently resulting in the progression of a malignant phenotype. A 
major effort has been made internationally to identify disease causing genes and 
mutations in Lynch syndrome. T  date, mutations within the following five DNA 
MMR genes have been implicated: hMLH1, hMSH2, hMSH6, hPMS1, hPMS2, 
hMSH3 (Chao and Lipkin 2006; Lynch and Lynch 2000; Lynch and De la Chapelle 
2003).   
 
Mutations in hMLH1 and hMSH2 account for majority of disease in Lynch families. 
The remaining genes, hMSH6, hPMS1 and hPMS2, are responsible for only about 
10% of the disease (Rowley 2005). All mutations (insertions, deletions, 
duplications or substitutions) identified internationally with the DNA MMR genes 
contributing to Lynch Syndrome are deposited in the Insight Mutation database, 
(http://www.insight-group.org) (ICG-HNPCC 2004). Another MMR gene database 
containing all published mutations in each MMR gene is also available at the 











1.3.2.2. Biallelic germline mutations  
 
Although homozygous germline mutations within the DNA MMR genes are rare, 
there have been cases described involving DNA MMR genes hMLH1, hMSH6 and 
more recently hPMS2.   
 
The childhood cancer syndrome (CCS) comprises haematological malignancies, 
brain tumours and neurofibromatosus type 1 (NF1), evident in individuals with 
biallelic mutations in a DNA MMR gene (Ricciardone et al. 1999; Whiteside et al.  
2002; De Vos et al.  2005; Felton et al. 2007; Poley et al.  2007; Tan et al.  2007; 
Kruger et al.  2008). The appearance of Café-au-lait spots (CALS) at a young age 
may lead to a misdiagnosis of classic NF1. The current hypothesis with regards to 
the occurrence of CALS is that during embryonic development, the NF1 gene is 
more susceptible to mutations as a result of deficient mismatch repair due to the 
large size of the gene. This is likely to result in the NF1 phenotype.  
 
The composite CCS syndromic phenotype usually has patients presenting with a 
haematological or brain malignancy in childhood and progressing to colorectal 
cancer into adolescence. Due to the germline MMR deficiency normal tissues of 
individuals show microsatellite instability (MSI) (De Vos 2005).  Wang et al.  (1999) 
describe a family in which children with hMLH1 deficiency presented with NF1, 
leukemia and lymphoma before the age of seven years (y).  
 
Two brothers from a consanguineous marriage presented with colorectal cancers 
at age 11y and 12y respectively (Muller et al.  2006). No other disorder was 
reported and the children showed a biallelic germline mutation in intron twelve of 
hMSH2. The authors state the phenotype is unusual as the characteristic 
malignancies were not evident. Although no expression or functional studies were 











expression of the functional MSH2 protein with reduced activity (Muller et al.  
2006).   
 
It has been suggested that biallelic germline mutations in hMLH1, hMSH2 and 
hMSH6 may occur within families who have a clear, autosomal dominantly 
inherited Lynch history (Menko et al.  2004). A homozygous 3 base-pair deletion in 
exon five of hMSH6 was described by Menko et al.  (2004). The child, from a 
consanguineous marriage, presented with CALS as well as a glioma at age 10y 
and rectosigmoid cancer at age 12y. 
 
A child, from a consanguineous family, with a homozygous mutation in hPMS2 
and presenting with Turcot syndrome (to be discussed in more detail later) was 
described by de Vos et al.  (2005). Another consanguineous family had a different 
germline homozygous mutation in hPMS2. This family had three children, all 
affected and presenting with CALS. Two of the three children developed rare 
neuroectodermal tumours while the third developed T-cell lymphoma.  
 
From the data reviewed above, it is evident that a biallelic germline mutation in a 
DNA MMR gene will inevitably lead to malignancy early in life. The exact 
malignancy will depend on the nature and severity of the mutation. In some cases, 
as described by Muller et al.  (2006), some mutations despite occurring 
homozygously, may only partially compromise protein function. This residual 
protein activity may only affect the most susceptible tissues. Therefore, it could be 
postulated, that only colorectal carcinomas and not the classical haematological 
malignancies would be prevalent due to the large number of carcinogens in 












1.3.2.3. Compound heterozygotes  
 
Though rare, there have been reported cases of compound heterozygosity in the 
DNA MMR genes. De Rosa et al.  (2002) described a non-consanguineous family 
in which the offspring had presented with Turcot syndrome, a variant of Lynch 
syndrome (discussed later). Analysis of the children had shown truncating 
mutations in each allele of the hPMS2 gene, inherited from each parent. The 
mutations in isolation had no clinical phenotype as seen in the parents or their 
blood relatives.  
 
A compound heterozygote hMSH6 was recently reported (Plaschke et al.  2006) 
where the patient presented with rectal cancer, at age 19y, and endometrial 
cancer, at age 24y. Although a non-sense mutation in one allele and a truncating 
mutation in the other allele were identified, further investigation showed residual 
expression of MSH6 in both tumour tissue types. The parents were found to be 
carriers of the mutations with no obvious related phenotype (Plaschke et al.  
2006).  
 
Rahner et al.  (2008) recently described a patient with two compound 
heterozygous mutations in hMSH6 (c.1806-1809 del AAAG and c.3226 C>T) who 
was diagnosed with vitiligo and systemic lupus erythematosus (SLE) at age 16y. 
At age 17y, the patient was diagnosed with four synchronous colorectal cancers 
(Rahner et al.  2008). The occurrence of auto-immune disorders within the patient 
is probably fortuitous though it has been documented that tumour-infiltrating 
lymphocytes are present in all Lynch tumours. The heightened immune response 
in Lynch tumours have been reported to show a better prognosis. Perhaps the 
appearance of vitiligo and SLE in the Rahner et al.  (2008) patient is due to 












Non-epithelial malignancies, hyperplastic endometrial tissue and ovarian 
carcinomas have also been reported in an hMSH2 compound heterozygous 
patient. The combination of a frameshift mutation, predicted to result in a truncated 
protein, and a heterozygous polymorphism were predicted to cause a polarity 
change in the protein interaction region. Family history uncovered multiple 
malignancies occurring in other family members including the probands sister 
(endometrial cancer) and father (colonic and gastric cancer).  All malignancies 
presented within the fourth decade of life (Huang et al.  2004). As the cancerous 
phenotype presented only in adult life, the compound heterozygous mutations 
within hMSH2 do not seem as detrimental as those discussed in hPMS1 and 
hMSH6, which presented during childhood and adolescence.  
 
From the cases reviewed above, it is noteworthy to observe that compound 
heterozygous mutations within the hPMS2 gene are more detrimental than those 
in the hMSH6 or hMSH2 genes. However it is not clear from the literature that the 
mutations reported all translate into equivalent functional compromise.  
 
Compound heterozygous mutations in hMSH2 resulted in the highest age of onset. 
Though the mutations occurred within a Lynch family, the patient presented with 
rare skin tumours.  As the skin is a highly proliferative tissue, similar malignancies 
are expected in MMR deficient individuals. However, skin tumours are extremely 
rare in Lynch families. The biology underlying the “resistance” of skin to succumb 
to malignancies in Lynch families is as yet poorly understood.  
 
1.3.3. Epigenetic silencing of a DNA MMR gene  
 
Epigenetic factors are also important in the loss of function of DNA mismatch 











progression of the disease and may result in either hypomethylation or 
hypermethylation. Global hypomethylation (decreased methylation, typically of 
repetitive sequences) results in chromosomal instability (Wong et al.  2007). 
Alternatively, hypermethylation results in increased methylation of sequences, 
particularly tumour suppressor genes inducing their silencing. Tumour suppressor 
genes commonly methylated in tumour tissue include hMLH1, APC and Rb – 
genes directly implicated in the initiation and progression of malignancy (Wong et 
al.  2007).  
 
A vast number of studies of microsatellite instability have shown that a wide range 
of sporadic cases may exhibit this phenotype (Rowley 2005). In addition loss of 
expression of the MLH1 protein has also been noted. These cases, with no family 
history of malignancy and not meeting the criteria for classification of Lynch 
syndrome, have been found, in some cases, to have both alleles of the hMLH1 
gene methylated. This methylation-related down-regulation of gene expression 
results in mimicking a Lynch Syndrome phenotype (Rowley 2005).  
 
More recently, reports of inherited germline epimutations in the hMLH1 gene 
described a mother and son who carried same epigenetic marker. This germline 
epimutation resulted in multiple tumours within the mother and conferred an 
increased risk of cancer in her son (Hitchins et al.  2007). This unusual finding 
indicates that epigenetic changes in the genome may be passed down through 
generations, rather than the expectation of epigenetic modifications in parents 












1.4. Tumourigenesis in MMR deficient cells  
 
Cancers resulting from defects within the DNA MMR system develop from the 
“mutator pathway” as opposed to the “traditional pathway”, which describes 
carcinogenesis via the loss of heterozygosity in critical genes as proposed by 
Fearon and Vogelstein (1991). The dubbed “Vogelstein pathway”, shown in Figure 
2, utilized colorectal cancer as a model for the study of carcinogenesis. The ability 
to capture various stages of carcinogenesis and to molecularly characterise these 
changes from normal colonic epithelium to a malignant tumour, allowed the 
sequence of events to be assessed.  It must, however, be noted that it is the 
accumulation of genetic changes, not the step-wise progression depicted below, 


























Figure 2:  “Vogelgram” of the adenoma to carcinoma sequence in colon cancer. The 
conversion of normal epithelium to a hyperproliferative epithelium in the 
colon results from the loss of the APC tumour suppressor gene on 
chromosome 5. Through the continuation of cell division, a small polyp may 
develop. An early, or Class I adenoma develops through the loss of DNA 
methylation in these cells. An intermediate (class II) adenoma develops via 
mutations within the K-ras gene on chromosome 12.  The conversion to a 
late (class III) adenoma results from the loss of the tumour suppressor gene 
DCC (Deleted in Colon Cancer) on chromosome 18.  Finally, the loss of TP53 
on chromosome 17 completes the conversion to a carcinoma. Metastasis 











The genetic model described above is based on chromosomal instability and 
estimated to account for 85% of all colorectal cancer cases (Hung and Chung 
2006). While the majority of colorectal cancers originate through the Vogelstein 
pathway (Figure 2), tumours of Lynch syndrome and some sporadic cancers 
originate via the “mutator pathway”. This pathway is characterized by a high level 
of microsatellite instability (Iglesias et al. 2006).  
 
1.4.1. Mutator Pathway  
 
During cell replication, the entire complement of double-stranded DNA has to be 
replicated with fidelity and integrity. As is expected, errors of various kinds occur 
during replication. Microsatellite regions (regions of repeated regions within the 
genome) are prone to the incorporation of errors during normal DNA replication. 
Instability of the microsatellites results in the insertion or deletion of repeated sets 
from either slippage of the DNA polymerase enzymes or through incorrect 
recombination processes in germ cells. These errors are corrected by a vigilant 
DNA MMR system. In the absence of an optimal DNA MMR system, cells 
accumulate mutations in their genome at a faster rate than normal cells (Lynch 
and Lynch; 1997).  
 
In cells where errors are not corrected, the instability of these microsatellite 
regions is observed (Huang et al.  2004). The exact mechanism of the Replication 
Error Phenotype (RER) to the initiation of carcinogenesis, is unknown. There is a 
distinction between the extent of microsatellite instability (MSI) within tumour 
tissue of patients. The recommended panel of markers used to test for MSI is 
known as the Betheseda Panel and currently incorporates five highly polymorphic 
markers. The instability of three or more of the markers constitutes a high 
microsatellite phenotype (MSI-H). A low microsatellite instability phenotype (MSI-











being unstable whereas a microsatellite stable phenotype (MSS) represents no 
marker of the panel being unstable in the tumour tissue (Lynch and De la Chapelle 
2003).  
 
It is thought that there are three basic levels of mutation within the mutator 
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Figure 3.:  The three basic levels of mutation in the mutator pathway. 
 
A second “hit” occurring in a DNA MMR gene that already has a germline mutation 
in the first level of the pathway results in defective DNA MMR repair and 
microsatellite instability. The second level of the pathway occurs when genes that 
affect tumour development have been influenced by the microsatellite instability. 
The final level of mutation in the mutator pathway includes all other altered genes 













Due to the alteration of many microsatellite regions, it has been difficult to predict 
which of those mutations play a causal role in the development of the malignancy. 
Duval et al.  (2001) statistically examined instability of coding sequences in high 
MSI human colorectal cancers. A sample of 25 candidate genes, each with a 
minimum of eight mononucleotide tracts, were chosen and analysed for mutations 
in these cancers. Thereafter a mutation order was established using the maximum 
likelihood statistical model. The study found that the next probable mutation in the 
mutator pathway (after loss of the DNA MMR gene) is the MMR gene hMSH3. 
This gene is not directly associated with Lynch syndrome (Duval et al.  2003).  The 
MSH3 protein forms, with MSH2, a complex known as MutSb which is involved in 
the repair of single base-pair deletion and mutations (Figure 1).  
 
Genetic instability in the mutator pathway results in mutations in the genome 
occurring more frequently due to a decreased rate of mutations being repaired 
(Cotran et al.  1999). There is an accelerated rate of carcinogenesis of tumours 
developing from the mutator pathway and this is thought to be due to the rapid 
accumulation of mutations (Fernandez-Peralta et al.  2005). It has been estimated 
that the normal progression from an adenoma to carcinoma for sporadic cases of 
colorectal cancer occurs within 8 -10 years, whereas the adenoma to carcinoma 
progression in colorectal cancer from Lynch syndrome patients can occur within 2 
– 3 years (Grady 2005; Lynch and De La Chapelle 2003). 
 
1.4.2. Interaction between Vogelstein and Mutator Pathways 
 
Salahshor et al.  (1999) aimed to elucidate the difference between the MSI-H and 
MSS pathways in a cohort of colorectal cancer patients. Mutations within the 
typical Vogelstein pathways genes and TGFBR2 were examined within the tumour 











mutated in any of the MSI-H samples yet there was frameshift mutations within 
TGFBR2 (Salahshor et al.  1999).  
 
There are certain families who clinically fulfil the Amsterdam criteria (Table 1) yet 
do not show MMR deficiency in tumour tissue. The tumour tissue from these 
families show distinctive molecular features such as mutations within K-ras genes 
and the mutation profile of Vogelstein pathway genes mimic that of sporadic 
malignancies.  
 
An integral part of the Vogelstein pathway is the mutation of TP53. This gene has 
been implicated in almost every malignancy and is an integral part in the optimal 
functioning of any cell. The TP53 gene has a mononucleotide repeat within the 
coding region and due to the nature of the mutator phenotype; it is expected that 
TP53 will be affected by the MMR deficiency (Woerner et al. 2005. Shitoh et al. 
(1998) demonstrated instability of the TP53 gene as a hallmark of the replication 
error phenotype in colorectal carcinomas (both sporadic and in Lynch syndrome).      
 
1.5. Tumour Spectrum in Lynch Syndrome  
 
Colorectal cancer is the archetypal cancer in Lynch syndrome and usually 
presents within the fourth decade of life yet, the occurrence of extracolonic 
cancers has also been observed (Lynch and De La Chapelle 2003). Consequently, 
the disease has been phenotypically characterized into two syndromes; namely 
Lynch syndrome I and Lynch syndrome II.  
 
Both syndromes, Lynch I and Lynch II, are primarily diagnosed by: an autosomal 
dominant mode of inheritance, an early age of onset and a germline mutation 











as Hereditary Site Specific Colon Cancer (HSSCC) and describes those 
predisposed families who present only with colon cancer, predominantly right-
sided colon cancer.  
 
Extracolonic cancers are a hallmark of Lynch syndrome II, often referred to as 
Cancer Family Syndrome (CFS) (Lynch and Lynch 1997). The recognition of 
extracolonic cancers within the tumour spectrum has led to the revision of the 
criteria traditionally used to identify affected pedigrees (Table 1).  
 
The screening and development of endometrial cancer within Lynch patients has 
been recognized and this malignancy is considered to present in the predisposed 
female member of a Lynch kindred. There has been controversy as to the 
inclusion of other extracolonic cancers within the Lynch tumour spectrum as there 
may be cases in which the tissue specific malignancy may be fortuitous or may 
segregate within the particular family as a result of a mutation in another gene 
causing susceptibility. To date, the inclusion of tissue sites in the Lynch tumour 
spectrum are based on elevated risks in individuals to a particular type of cancer. 
(Watson and Riley 2005). Gastric, small bowel, hepatobiliary tract, upper 
urological tract, ovarian, endometrial and brain cancers were defined as part of the 
HNPCC tumour spectrum (Watson and Riley 2005).    
 
1.5.1. Gynaecologic cancers 
 
Endometrial cancer was one of the malignancies first described by Dr Warthin in 
the analysis of Family G and together with colorectal cancer; it is the second most 
prominent cancer in Lynch syndrome (Banno et al.  2004, Douglas et al.  2005). Lu 
et al.  (2005) documented that in females, the development of endometrial cancer, 
and to a lesser extent ovarian cancer may equal or even exceed the risk of colon 












There have been multiple studies attempting to correlate the occurrence of 
endometrial cancer with the primary germline mutation (Gonzalez-Aguilera et al.  
2003, Plaschke et al.  2004, Goodfellow et al.  2003). It has been suggested that 
the female members of families segregating with hMSH2 mutations present with 
endometrial cancer more frequently than any other Lynch-associated cancer 
(Gonzalez-Aguilera et al.  2003) yet other studies have shown the presence of this 
malignancy regardless of the germline MMR gene or mutation. In particular, a 
study performed in 2003 demonstrated that female patients with hMSH6 mutations 
present with endometrial cancer significantly earlier than women in the general 
population (p = 0.04) (Goodfellow et al.  2003). Malander et al.  (2005) found 
truncating mutations in hMSH6 confer a high risk for the development of a 
gynaecologic cancer. There is no consensus as to the genotype – phenotype 
relationship in Lynch syndrome and it is recommended that females harbouring a 
predisposing mutation to the disorder undergo routine gynaecologic screening 
(ICG-HNPCC 2004).   
 
Kuismanen et al.  (2002) suggested that the genesis of gastrointestinal and 
endometrial cancers in patients predisposed to Lynch syndrome, occur through 
different routes. Interestingly, however, both malignancies are characterised by 
MSI. The study focused on MSI and mutations within certain microsatellite-rich 
genes and found that changes in different target loci could distinguish between 
colorectal and endometrial cancer (Kuismanen et al.  2002).  
 
Pathologically, Van den Bos et al.  (2004) demonstrated that Lynch-related 
endometrial cancers differ considerably from sporadic endometrial cancers. Lynch-
related endometrial cancers show poor differentiation, Crohn-like lymphoid 
reactions, lymphoangioinvasive growth and tumour-infiltrating lymphocytes; 













Molecularly, Lynch-related endometrial cancer and sporadic endometrial cancer 
seemed to be comparable (Rijcken et al.  2007). The group examined the 
expression of various cell cycle and apoptosis proteins and only found the 
expression of Cyclin B1, a cell cycle regulatory gene, is more highly expressed in 
Lynch endometrial cancer. The apoptosis related protein BAX was significantly 
absent in three Lynch cancers when compared to the presence of the protein in 
sporadic cancers (p = 0.013). The study also suggested a trend toward a higher 
proliferation rate in Lynch cancers. Although the Lynch-related endometrial cancer 
were determined through family history and inclusion by the revised Amsterdam 
criteria, upon further investigation only ten of eighteen samples were shown to 
have DNA MMR defects (six samples had mutations in hMLH1, two in hMSH2 and 
two in hMSH6) (Rijcken et al.  2007). Unfortunately there is no mention of 
pathology or IHC investigations of the samples where the DNA MMR genes were 




Female Lynch patients have an eight to fifteen percent risk of development of 
ovarian, an estimated ten-fold increase in risk compared to that of the general 
population (So g et al.  2006). Interestingly Geisler et al.  (2003) reported that 
16.8% of all ovarian carcinomas have defects in the DNA MMR system. Suzuki et 
al.  (2001) showed that defects in the DNA MMR system are involved in the 
development and progression of ovarian malignancies – notably in the genetic 
alterations introduced by the defective system. In a large multicenter study of 
common variants in MMR genes there was an observed association between a 
specific variant in the DNA MMR gene hPMS2 (p = 0.046) whereas variants in the 
other DNA MMR genes (hMLH1, hMSH2, hMLH3, hMSH3, hMSH6 and hPMS1) 











mutations in ovarian carcinomas, hypermethylation of the hMLH1 promoter has 
also been identified (Geisler et al.  2001). 
 
1.5.2. Hepatobiliary Cancers  
 
The hepatobiliary tract is composed of the pancreas, biliary system and liver. 
Lynch et al.  (1985b) first described the occurrence of pancreatic cancer in a 
Lynch family, evident through five generations.  
 
Genetics of Hepatobiliary Cancers  
In particular, liver, or hepatocellular, cancers have many environmental risk 
factors. For example, chronic viral hepatitis confers a high risk of hepatocellular 
cancer. Alpha1-antitypsin deficiency, Non-alcoholic fatty liver disease, 
haemochromatosis as well as alcohol and exposure to toxins may also result in a 
malignancy (Teufel et al.  2007).  
 
Moinzadeh et al.  (2005) found amplifications of certain chromosomal positions 
(1p, 8q, 6p, 17q) in the majority of sporadic hepatobiliary malignancies. In addition, 
deletions of chromosomal regions 16q, 4q, 17p and 13q were also found. At the 
gene level, point mutations in the tumour suppressor gene TP53 are evident 
(Teufel et al.  2007).  Mutations within the components of the Wnt, Ras and TGFB-
signalling pathways have also been shown to promote the development of 
hepatocellular carcinoma. The Wnt pathway functions in cell to cell interaction and 
the regulation of proliferation.  In addition mutations within the tumour suppressor 
gene Rb has been implicated in the disease (Moinzadeh et al.  2005).  
 
Though the initiation of sporadic hepatocellular carcinomas is currently unknown 











involves all the major components in the disease as found in the genetic model 
proposed by Fearon and Vogelstein (1991).   There are also components of the 
tumourigenesis pathway similar to the mutator pathway as seen by the mutation of 
the TGFB signalling pathway.  
 
1.5.3. Gastric Cancers  
 
Gastric cancer was originally described in association with Lynch syndrome in 
Family G in 1913 (Douglas et al.  2005). Though gastric cancer is rare in Lynch 
families described to date, studies have Chinese, Korean and Brazilian descent 
have a higher risk for both gastric and hepatic cancer as compared to that of 
endometrial and small intestinal cancer (Cai et al.  2006, Wang et al.  2006).   
 
A recent study by Gylling et al.  (2007) found that MSI gastric cancers from both 
MMR-positive and MMR-deficient individuals showed significant mutations within 
repeat-tracts of genes (p <0.001) and a higher methylation index than that of 
sporadic MSS gastric cancers.  Additionally, there was a significant association 
between frame-shift mutations in microsatellite rich regions of growth regulatory 
genes (p = 0.0001) as well in MSI tumours (Gylling et al.  2007). The Gylling et al.  
(2007) study provides further insight into the molecular differences between MSI 
and MSS malignancies. However, the genetic signature of MSI tumours – 
regardless of site of cancer – still remains unanswered.  
 
Genetics of Gastric Cancer 
Environmental or external factors contribute considerably in the development of all 
diseases and gastric cancer is no exception. The bacterium Helicobacter pylori is 












Microsatellite instability in gastric carcinomas (Garay et al.  2004) is rare although 
there have been cases of MSI-H gastric carcinomas documented, in which there is 
frequent loss of a DNA MMR gene, hMLH1 and hMSH2. Additionally, mutations 
within TGBR2, BAX, IGF2R, E2F4, hMSH3 and hMSH6 are frequent. These 
mutations are commonly found in Lynch colorectal cancers (El-Rifai and Powell 
2002, Rafau and Powell 2002).  
 
Sporadic gastric cancers are found to have mutations in TP53, APC, B-catenin 
and overexpression of growth factors and receptors (such as c-MET, HER-2/neu 
and EGFR/K-sam) – the molecular pathology similar to the Vogelstein pathway 
(El-Rifai and Powell 2002).   
 
1.5.4. Small intestinal cancers  
 
A study by Love first included cancers of the small intestine in the Lynch spectrum 
of cancers. The inclusion was then verified by Lynch et al.  (1985a). In 1998, an 
international collaboration nto the epidemiology of intestinal cancers in Lynch 
families showed that this malignancy had an age of onset almost two decades 
before that of the general population (Rodriguez-Bigas et al.  1998). In addition, 
small intestinal cancers showed a gender bias towards males.  
 
Genetics of Small intestinal cancers 
Small intestinal cancers comprise of cancers within the ileum, duodenum and 
ileum and are a common occurrence in familial adenomatous polyposis (FAP) – a 
hereditary form of colorectal cancer. However, these malignancies are rare in the 
general population (Lynch et al.  1985a). In Lynch syndrome, the majority of 












Malignancies of the gastrointestinal tract may be attributed to hereditary conditions 
such as Lynch syndrome or FAP. Gastrointestinal Stromal tumours (GIST) may be 
another type of tumour occurring throughout the intestinal tract. The genesis of 
small intestinal tumour is similar to that of colonic carcinomas, using the 
Vogelstein pathway as a model.  
 
1.5.5. Upper Uroepithelial Tract  
 
Loss of hMSH2 has been found in 60% of microsatellite instable upper 
uroeptihelial cancers (Ericson et al.  2005) and thus there are recommendations to 
screen families with this germline mutation for urinary tract carcinomas. Various 
studies have shown that Lynch families have an increased risk for the 
development of transitional cell carcinoma of the ureter, renal pelvis and calyx. 
These studies also concur that these patients do not have an increased risk for the 
development of bladder cancer (Sijmons et a. 1998, Lynch et al.  2003, Hartmann 
et al.  2003). The life-time for the development of an upper uroepithelial tract 
cancer in Lynch patients is estimated to be between four and ten percent.  
 
Genetics of Upper Uroeptihelial Tract Cancer 
The occurrence of an upper uroepithelial tract malignancy is rare. As with most 
cancers, involvement of TP53 and Rb pathways is evident (McGrath et al.  2006).   
 
Ruopret et al.  (2005) reviewed upper uroeptithelial tract cancers and found that 
MSI and expression of MSH2 could be effectively used prognostically. Loss of 
expression of E-cadherin was also found to contribute to the overall survival rate 
(). When abnormal karyotypes were further studied, loss of chromosome nine was 











by Fadl-Elmula (2005). Tumour suppressor genes found on chromosome nine 
include apoptosis related genes such as p16.  
 
Wu et al.  (2007) reported that individuals with single nucleotide polymorphisms 
(SNPs) with in DNA repair genes and cell cycle control controls were predisposed 
to the development of bladder cancer. Yet, there was a bias toward certain 
environmental effects (for example smoking); together the environmental effect 
coupled with a high-risk allele was found to have a multiplicative risk factor for the 
individual.   
 
Mutations within detoxification genes have also been implicated in the 
predisposition to and the development of bladder cancer (McGrath et al.  2006).   
 
1.5.6. Brain cancer  
 
Brain cancer is extremely rare in Lynch families. A study by Vasen et al.  (1996) 
showed a statistically significant increase (p = 0.04) in the risk of brain tumours in 
Lynch families compared to the background population.  
 
Mutations within the MMR gene hPMS2 have been implicated in Turcot syndrome, 
a rare variant of Lynch syndrome. Turcot syndrome is characterized by 
manifestation of cancer in both the colorectum and brain (Lynch et al.  2003).  
 
Genetics of Brain Cancer 
Loss of chromosome 17 and in particular the TP53 which resides there is an 
important factor in the development of brain malignancies. Gliomas are the most 











has been described (Louis 2006). Several other tumour suppressor genes have 
been implicated in the development and initiation of brain cancers and these are 
thoroughly reviewed in Louis (2006).  
 
1.5.6.1.Turcot syndrome  
 
The appearance of colorectal carcinomas coupled with brain cancers is 
characterized as Turcot syndrome. Mutations within the hPMS2 gene have been 
associated with this syndrome (Hamilton et al.  1995).  
 
1.5.7. Muire Torre Syndrome 
 
Muire Torre Syndrome (MTS) is a rare variant of Lynch syndrome. This syndrome 
is characterised by sebaceous adenomas, sebaceous carcinomas and multiple 
keratocanthomas coupled with colorectal cancer (Lynch et al.  2003). Mutations 
within hMSH2 have been associated with MTS.  
 
1.5.8. Genotype – Phenotype correlation 
 
Due to the diverse number of genes and cancerous manifestations that are 
implicated in this disorder, there have been several investigations into determining 
the genotype – phenotype relationship of the mismatch repair mutation and 
occurrence of specific cancers in families (Grady 2005).   
 
A number of these studies (Plaschke et al.  2004; Rodriguez – Moranta et al.  











mutations seem to have a later age of onset of colorectal cancer. Female 
members have a lower risk for CRC but have a higher risk for endometrial cancer. 
hMSH2 mutation carriers also seem to have a higher risk of extracolonic cancers; 
that is cancers of the upper urothelial tract, ovary, and gastric cancer (Vasen et al.  
1996).  Vasen et al.  (2001) showed that hMSH2 mutation carriers had a higher 
lifetime risk of developing any cancer in comparison to hMLH1 mutation carriers (P 
< 0.01). In addition, Gonzalez – Aguilera et al.  (2003) investigated the effects of 
mutations within different DNA mismatch repair genes on the development of 
extracolonic cancers in HNPCC. Goecke et al.  (2006) studied the German 
HNPCC cohort and reported that in males with an hMSH2 predisposing mutation, 
there was a correlation to prostate cancer, a cancer not found within the Lynch 
tumour spectrum.  
 
Germline mutations resulting in the expression of defective proteins were shown to 
exhibit an increase in the frequency of extracolonic manifestations when compared 
to germline mutations that resulted in only monoallelic expression of the wild type 
hMLH1 allele in a Danish cohort (Jager et al.  1997). In addition, the group 
reported an intronic hMLH1 germline mutation, which resulted in silencing of the 
allele. This particular mutation presented with a reduced frequency of extracolonic 
cancers when compared to other mutations in the same cohort (Jager et al.  
1997). The authors hypothesise two potential disease modifying mechanisms: the 
first mechanism involves the presence of a modifier gene close to hMLH1 that can 
potentially compensate for MMR. The second mechanism involves a dosage effect 
in which the mutant allele is silenced due to the mutation. The intronic germline 
mutation reported in the study seems to adhere to the proposed second mutation 
as individuals with a mutation that results in expression of a defective protein 
exhibited a high number of extracolonic malignancies (Jager et al.  1997). 
However, the mutation that results in a defective protein is the hMSH2 gene – of 












The cumulative incidence of extracolonic cancers manifesting within HNPCC 
families was further investigated by Lin et al.  (1998). This study showed 
significant evidence in associating extracolonic cancers to individuals with hMSH2 
germline mutations (48% hMSH2 vs 11% hMLH1 patients with extracolonic 
cancers, p = 0.016).  
 
More recently, a genotype-phenotype association was attempted using a family 
with an hMLH1 mutation and a family with an hMSH2 mutation (Havarlsson et al.  
2006). Tumours from the family members were characterized and no correlation 
was obtained. In fact, both inter-tumour and intra-tumour heterogeneity was 
observed histopathologically and immunohistochemically (Halvarsson et al.  2006).  
 
In a recent study into the gene-related cancer spectrum in families with Lynch 
syndrome, Geary et al.  (2007) analysed ll malignancies reported in a cohort of 
Lynch syndrome families. The study concluded that colorectal and endometrial 
cancers were prominent in these families, regardless of primary mutation. hMSH2 
mutation carriers seemed to have a broader tumour spectrum of cancers than 
hMLH1 mutation carriers. It was also evident that certain cancer types clustered 
within families.  
 
The inclusion of cancers in the tumour spectrum of Lynch syndrome is based on 
incidences as opposed to the molecular pathogenesis of malignancy at each 
anatomic site.  Monglat-Artus et al.  (2006) describe a patient with a hMSH2 
germline mutation who presented with multiple primary cancers of the colon, upper 
urinary tract and endocervix. These cancers were shown to be MSI and loss of the 
MSH2 protein was demonstrated. In addition, the patient also presented with a 
renal papillary cancer. On further investigation, this cancer was unrelated to the 
DNA MMR deficiency as the MSH2 protein was present and the tumour was MSS 












Miyaki et al.  (1997) found that mutations in hMSH6 can lead to a more benign 
form of Lynch Syndrome and thus may be under-diagnosed or present much later 
than usual It has been further documented that mutations in hMSH6 in Lynch 
syndrome families result in a greater frequency of gynecologic cancers among the 
female members of those pedigrees (Cederquist et al.  2005).  
 
There is a vast phenotypic heterogeneity seen within Lynch tumours,  both intra- 
and inter-individual. Halvarsson et al.  (2006) reported variable histopathology and 
immunohistochemical expression of B-catenin in Lynch related colorectal, 
endometrial and ovarian cancers. Due to the identical germline mutation in the 
MMR gene, it was hypothesized that independent modifier genes, which were 
affected by frame-shift mutations due to the r plication error (RER) phenotype 
(microsatellite instability), influence the histopathology and morphology of these 
Lynch tumours (Halvarsson et al.  2006). As indicated in other studies, the modifier 
genes affected are most likely to be tissue specific.  
 
When correlated with its function, the promiscuity of the spectrum of tumours seen 
in hMSH2 mutation positive individuals seems obvious. A MSH2 complex (either 
the MSH2/MSH6 complex or MSH2/MLH3 complex) binds to the replicating DNA 
and scans for any defects (Figure1) (Chao and Lipkin 2006). Thus, anomalies 
within the final product should result in a wider variety of tumours; the MSH2 
protein is one of the first MMR proteins in the pathway and is critical in the efficient 
functioning of the system in every cell type.  
 
Germline mutations resulting in the expression of defective proteins were shown to 
exhibit an increase in the frequency of extracolonic manifestations when compared 
to germline mutations that resulted in only monoallelic expression of the wild type 











(2008) aimed to statistically characterise the risk of extracolonic malignancies in a 
large, pooled cohort of mutation carriers (either hMLH1 or hMSH2 mutation 
carriers in four study centres (Finland, USA, Holland and Denmark). Overall, 
Watson et al. (2008) found individuals with MSH2 mutations to be at a higher risk 
for urologic cancer (males) (p<0.0001) and ovarian cancer (females) (p<0.006).  
 
In light of this, analysis of published founder mutations within the hMLH1, hMSH2 
and hMSH6 genes were attempted with the aim of possibly elucidating mutations 
occurring within a specific area leading to certain malignancies. The genes hMLH1 
and hMSH2, accounting for the majority of HNPCC, show a variety of founder 
mutations globally. The results of this can be seen in Tables 2 and 3 (hMLH1 
founder mutations and hMSH2 founder mutations respectively). Mutations were 
regarded as founder mutations if haplotype studies were performed and the 
mutation could successfully be dated back to at least 5 generations.  
 
Overall, the founder mutations found in both genes (hMLH1 and hMSH2) result in 
an array of tumours and some of the tumours encountered do not fall into the 
HNPCC tumour spectrum (Table 2, Table 3). When compared to the results of the 
hMLH1 founder mutations, mutations within the MSH2 gene are more 
promiscuous. Every mutation the hMSH2 gene results in at least three different 
tumour sites whereas each mutation within the hMLH1 gene results in at least one 
tumour site.  
 
Examination of the effect of founder mutations within populations is essential in 
order to extract vital information regarding the biology of the disease. A variety of 
cancers were found with each founding mutation and therefore a specific region of 
the protein mutated resulting in a specific range of malignancies is not possible. In 
addition, the founding mutations do not comply with the assumption that hMSH2 











observed that extracolonic cancers occur more frequently (not exclusively) in 
patients with hMSH2 mutations. A possible setback was the lack of clinical data in 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.6. Pathology of Lynch Syndrome Cancers 
 
Colonic and extracolonic tumours formed in Lynch syndrome are poorly 
differentiated and exhibit a large amount of mucoid and signet-cell features as well 
as infiltrating lymphocytes within the tumor. A feature of these tumors is that MSI is 
evident and the DNA MMR gene mutated is absent through immunohistochemical 
staining (Lynch and Lynch 2000, Jass 2007).  Although MSI can occur in other 
non-familial forms of cancers (for example sporadic colon cancers with hMLH1 
epigeneticaly silenced), it is not a consistent feature (Hitchins et al.  2007).  
 
It is evident that there are differences in early tumourigenic events between Lynch 
syndrome colonic adenomas in comparison to their sporadic counterparts (Rijcken 
et al.  2007). Apart from the clear pathological observations, more molecular 
differences are being elucidated. Rijcken et al.  (2007) showed that certain cell 
cycle and apoptosis proteins have differential expression in Lynch syndrome 
colonic adenomas compared to sporadic colonic adenomas. Studies investigating 
occurrence of endometrial cancer in Lynch patients have also shown molecular 
differences when compared to sporadic endometrial carcinomas (Lax 2004, Van 
den Bos et al.  2004, Ricjken et al.  2005).  
 
In contrast, a study profiling the target gene mutation profile in colorectal, gastric 
and endometrial high MSI tumours, demonstrated that there are tissue specific 
differences (Duval et al.  2002). However, the study did find that there are certain 
target genes mutated in all the tumours studied. Once these genes have been 
mutated, it was hypothesized that the other mutations were dependant on the 
location of the tumour (Duval et al.  2002). The tumour samples used in the study 
were not necessarily from Lynch syndrome patients but were chosen on the basis 
of their MSI, thus the samples may have been MMR deficient due to epigenetic 











genes for mutation in MSI-H tumours, regardless of site of cancer (Duval et al.  
2001, Duval et al.  2002).  
 
Apart from the differences in the site of cancer in individuals predisposed to Lynch 
Syndrome, the age of onset of the cancer may differ significantly. Although most 
individuals present in the fourth decade of life, there are cases in which the 
disease presents in the second or third decade of life (Westaphalen et al.  2005).  
 
1.7. Research in Lynch Syndrome  
 
Since the setting of criteria for identifying the Lynch phenotype (Amsterdam and 
Bethesda criteria) large Mendelian families were followed up. These families 
facilitated the localisation and ultimate identification of the genes involved in the 
phenotype. The genes involved were identified between 1993 and 1995 (Rowley 
2005).  
 
In biological systems, usually the optimal functioning of a gene or protein depends 
not only on its integrity but also on the molecules (or the responsible genes) 
upstream of it in a regulatory or biochemical pathway, or on factors that enhance 
or reduce its function.  These factors are now being thoroughly studied and these 
include low penetrance genes (or modifier) genes (Ilyas et al.  1999, Dribble and 
McCabe 2000, De Jong et al.  2002).  
 
The majority of studies in Lynch syndrome have focused on the variability seen in 
the age of onset of symptoms in predisposed families. The occurrence of specific 
extracolonic cancers and the molecular pathology of these cancers in terms of a 












1.8. Aims and Objectives 
 
The aim of the study is ultimately to determine the molecular pathology of 
extracolonic cancers in Lynch syndrome and to elucidate whether or not the 
occurrence of these extracolonic cancers is a direct result of the mismatch repair 
deficiency.  
 
The working hypothesis of this study relies on the mechanism of DNA MMR 
activity. As discussed previously, mutations within DNA MMR genes that 
consequently result in a breakdown of the repair system exhibit unstable regions in 
microsatellite rich areas of the genome. Manipulating this fact, a panel of 
microsatellite rich genes will be assessed in germline DNA and the corresponding 
tumour DNA of the available Lynch-associated malignancies. This cohort will also 
be subjected to Methylation specific – Multiplex Ligation-dependant Probe 
Amplification (Ms-MLPA) in order to attempt to characterize a pattern of 
methylation in these patients. The objective of this study is to evaluate and 
potentially molecularly characterize Lynch-associated tumours. If successful, this 
method may be employed in pathology laboratories and other diagnostic centres 
to appropriately diagnose and initiate treatment. Furthermore, the results of this 
study may direct future drug development.  
 
Prior to the microsatellite-rich genes and Ms-MLPA study, a potential modifier for 
site of cancer will be assessed in a large cohort. Both patients predisposed to 
Lynch syndrome and controls will be assessed for the modifier genotypes. 
Potential modifiers for site of cancer may be possible diagnostic and management 
essentials by directly treatment and screening regimes.  
 











Akin to many cancers prevalent today, the earlier the disease is diagnosed, the 
better the prognosis and in individuals with germline mutations thus resulting in 
better the management of the symptoms. It is therefore imperative to diagnose the 
disease and identify predisposed families as early as possible to allow for the 














hMLH1 -93G>A Promoter polymorphism as a phenotypic 
modifier of Lynch Syndrome 
 
2.1 Introduction  
 
The current study is focused on the occurrence of extracolonic cancers in Lynch 
syndrome. Phenotypic and genotypic heterogeneity are evident in Lynch 
syndrome, further complicating both diagnosis and treatment. The phenotypic 
heterogeneity observed in the syndrome has implications on the screening 
regimens and management of the disease.  
 
Low penetrance or modifying genes are genes which secondarily influence the 
ultimate phenotype of a disease. These genes may potentially be markers for the 
development and severity of diseases (Kotnis et al.  2004). SNPs in these genes 
may affect functional activity and may thus pose an increased risk to cancerous 
growth (Kotnis et al.  2004). Genetic variation in key pathways may hold the key to 
explaining the initiation of malignancy, rate of carcinogenesis and the resistance or 
susceptibility of the individual (Kotnis et al.  2005).  
 
Although many studies in Lynch syndrome, have investigated associations 
between the variation in the age of onset of malignancy and modifier genes (Bala 
and Peltomaki 2000; Maillet et al.  2000; Felix et al.  2006), no known modifier 
studies have been found with respect to variations in the site of cancer. The 
variations in the site of cancer may, in part, be explained by the primary 
predisposing mutation in the DNA MMR genes. Mutations in certain DNA MMR 











et al.  1996). However, this is not always the case. Although originally though to be 
mostly due to mutations in hMSH2 and hMSH6, extracolonic cancers have been 
reported in carriers of germline mutations in hMLH1 (Nystrom-Lahti et al.  1995; 
Thiffault et al.  2004), thus blurring the lines between the conservative phenotype 
(solely colorectal cancer) and the promiscuous phenotype (widest range of 
extracolonic cancers).  
 
Recently, a promoter polymorphism in the DNA MMR gene hMLH1 gene has been 
implicated in an increased risk of colorectal and endometrial cancers (Harley et al.  
2008). This c.-93G>A polymorphism, occurs 93 bases away from the transcription 
start site of the gene.  
 
The hMLH1 c.-93G>A polymorphism has also been associated with an increased 
risk of microsatellite unstable colorectal cancer in two different populations (Raptis 
et al.  2007). The case-control study was undertaken in Ontario and New 
Foundland and the OR for the each populations’ heterozygosity were 1.84 (95% 
CI: 1.20 – 2.83) (p = 0.001) and 2.56 (95%CI: 1.14 – 5.75) (p = 0.003) 
respectively.  
 
More recently, Harley et al.  (2008) reported an association between the hMLH1 
c.-93G>A polymorphism and risk for epithelial ovarian cancer (OR: 1.5, p = 
0.0005). The study was performed on a mixed white North American population 
(Caucasian and Hispanic) in which the variant is present in at least 31% of the 
female population (Harley et al.  2008).  
 
Beiner et al.  (2006) examined the effect of hMLH1 and hMSH2 variants on the 
risk of developing endometrial cancer in a cohort of patients already diagnosed 
with endometrial cancer. The study found that women who carry at least one of the 











variant. Heterozygous (GA) women have an odds ratio (OR) of 1.4 (P = 0.008) and 
homozygous variant (AA) women have an OR of 1.9 (P = 0.009); whereas 
homozygous wildtype (GG) women have an OR of 1.  
 
The aim of this particular study is to assess the effect of the hMLH1 c.-93G>A 
polymorphism in a cohort of Lynch syndrome patients in order to investigate an 
association between the variant and site of cancer as well as age of onset of the 
affected patients.   
 
2.2 Materials and Methods 
2.2.1 Cohort selection  
 
The cohort for this study was selected from the Colorectal Cancer Database in the 
Division of Human Genetics, at the University of Cape Town (UCT). The database 
contains information on individuals mostly from the Western Cape Province of 
South Africa, and was initiated in 1987 when the first family with Lynch syndrome 
was identified (Ramesar et al.  2000).  
 
The database currently contains information on individuals recruited for 
investigation of DNA MMR genes (under 50 years (y) of age), or if they had a 
family history of colorectal cancer (CRC). In some instances, unaffected family 
members are also in the database. The largest families are usually those with a 
mutation already identified in the proband (usually affected). Information archived 













For inclusion into the cohort, patients had to have a predisposing mutation in the 
hMLH1 gene, specifically the C1528T founder mutation previously described in 
this cohort (Ramesar et al.  2000). Ethical approval of the cancer study was 
obtained. Patient consent was granted for the use of biological samples to be 
utilized in research studies by every patient.  An example of the consent form is 
provided in Appendix 1.  
 
Ninety-three individuals with the C1528T germline mutation in the hMLH1 gene 
were included in the study. Of the individuals selected, 38 were affected with 
cancer and 55 were, at the time of study, unaffected (cancer-free).  
 
As a control group, 97 individuals were chosen. Most of these patients did present 
with a Lynch associated malignancy at a young age and were subsequently 
recruited into the Lynch study cohort but on further investigation, no germline 
mutation within one of the three DNA MMR genes (hMLH1, hMSH2 and hMSH6) 
was identified. Also included in the control cohort are those individuals who are 
related to a proband with a known predisposing germline DNA MMR gene 
mutation. In this control group, 77 were affected with cancer and 20 individuals 
were unaffected (cancer -free) at time of study.  
 
2.2.2. DNA Isolation and Integrity  
 
Genomic DNA was isolated from peripheral blood lymphocytes using the 
Puregene™ DNA Isolation Kit (Gentra Systems, USA). Two samples of blood 
were obtained by venepuncture from the patient in 10ml EDTA tubes. The DNA 












The quality and quantity of the DNA was measured using a NanoDrop 1000 
spectrophotometer. The concentration of the stock samples was calculated using 
NanoDrop1000 software (NanoDrop Technologies).  The amount of protein and 
organic solvent contamination within the sample was reflected by the ratio of the 
wavelength for maximum absorbance of DNA (A260) and the wavelength for the 
maximum absorbance of protein (A280) or organic solvents (A230). Viable stock 
solutions were diluted to a final working concentration of 100 nanograms per 
microlitre (ng/µl) for use in further investigation. The diluted samples were 
assessed for integrity by gel electrophoresis. Two hundred nanograms of the 
diluted sample was mixed with three microlitres of loading dye (Appendix 2.1) and 
then loaded onto a one percent agarose gel (Appendix 2.2). The gel was 
electrophoresed at 120 volts (V) for 30 minutes and visualised on a UviPro 
UviGold Transilluminator (Whitehead Scientific, USA).  
 
2.2.3. Identification of Gene Sequence and Primer design  
 
Information regarding the gene sequence, SNPs identified in the sequence and 
information about the gene were accessed from the NCBI Gene website (URL: 
http://www.ncbi.nih.gov) (Version GI:89161205) and the Ensembl website 
(http://www.ensembl.org) (Version Ensembl 48).  Information from these websites 
were merged to create an annotated gene sequence. The program used for the 
annotation was Annotv9, created by Dr Rebello (Division of Human Genetics, 
UCT, Personal communication).  
 
For analysis of the genomic regions of interest target fragments of these genes 
required amplification by the Polymerase Chain Reaction (PCR) (Mullis et al. 
1986). The genomic region of interest in the present study was identified from the 











(a minimum of 60 bases on either side of the region of interest was included). 
Ideally, the amplified product should be between 100 and 500 base-pairs long.   
 
The selected region was interrogated with the primer design program, Primer 3 at 
the following URL: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Primer 
3 (Version 2004) is a free web-based program developed and supplied by the 
Whitehead Institute for Biomedical Research (Rosen and Skaletsky 2000). The 
following parameters were placed on the design of the primer using Primer 3: 
length of the primer was specified to be between 18 and 22 bases, the melting 
temperature of the primer between 55 degrees Celsius (°C) and 60°C, the 
maximum number of repeats to be included as three, and mispriming was not 
required.  
 
The Primer 3 output was then analysed using the free web-based program IDT 
Oligo Analyzer. (URL: http://www.idtdna.com/analyzer/ 
Applications/OligoAnalyzer/). For the analysis of the primer pair, each half was 
assessed for the characteristics of the primer (e.g. melting temperature of the 
primer, length and GC content). The ability of the primer to form dimers with itself 
and the second primer in the reaction as well as the degree of self-
complementarity of the primer was also assessed. Finally, a NCBI BLAST search 
was also performed to ensure the primer would not bind to other regions on the 
genome The Nucleotide-Nucleotide BLAST search was performed online at the 
NCBI webpage. The program searches sequenced genomes (in this case, the 
human genome was specifically chosen) for homologous areas to which the 
primer can alternatively bind (Altschul  et al. 1990).  The program can be found at 
the following URL: http://www.ncbi/nih.com/BLAST. The finalised primer set (seen 












Table 4: Primer sequences 
 
 PRIMER SEQUENCE LENGTH Tm %GC OD/ml 
hMLH1_EXON1_F GCTGTCCAATCAATAGCTGCCGC 23 59 57 4.265 
hMLH1_EXON1_R GCTGTCCAATCAATAGCTGCCGC 21 58 62 4.672 
 
2.2.4. Polymerase Chain Reaction  
2.2.4.1. PCR Optimization  
 
Prior to amplification of the cohort and mutation detection the PCR was optimized 
to determine the optimum temperature, concentration of reagents and cycling 
conditions. The first optimization procedure performed was to run the reaction 
across a temperature gradient. For each PCR reaction a control sample was used 
in a standard PCR reaction as described. A volume of 25 microlitres (µl) of 
identical PCR reaction mix was placed in twelve PCR tubes. The Multigene PCR 
machine (Whitehead Scientific, USA) was set at a 1°C interval starts from a 
minimum temperature of 50°C.  
 
2.2.4.2. Amplification  
 
All reactions were made up to a final volume of 25µl. A standard reaction 
contained 100ng of template DNA, 0.1 units (U) of GoTaq DNA polymerase 
(Promega, USA), 1 x GoTaq Polymerase Buffer (pH 8.5, 1.5mM MgCl2 per 
reaction), a final concentration of 200 micromolar (µM) deoxyribonucleotide 
(dNTPs) (Bioline, USA), a final concentration of 0.4µM of each primer (forward and 











The standard cycling conditions used for the PCR included: an initial denaturing 
step at 95° C for 5 minutes, 30 cycles of amplification, which involved a denaturing 
step at 95° C for 30 seconds; an annealing temperature of 57° C for 30 seconds 
and an elongation step at 72°C for 40 seconds. An additional elongation step at 
72°C for 7 minutes ensured completion of the reaction.  
 
To ensure the correct-sized fragment was obtained after amplification, a molecular 
weight marker was electrophoresed alongside the amplified products. The 
GeneRuler 100 base-pair (bp) molecular weight marker (Fermentas, USA) was 
employed for all resolution of fragments on an agarose gel. The marker was used 
at a concentration of 0.05 micrograms (µg)/ µl (Appendix 3).  
 
2.2.5. Resolution of DNA fragments 
 
PCR products and products of restriction enzyme digestion were detected by 
Agarose Gel Electrophoresis (AGE).  AGE functions by exploiting the charge of 
DNA. DNA is a negatively charged molecule and when placed in an electric field, 
migrates towards the positive electrode, with smaller DNA molecules moving 
faster through the gel.  DNA fragments migrate through a porous agarose gel on 
the basis of size (Sambrook et al.  1989). Low electroendosmosis agarose was 
supplied from Roche Diagnostics (Roche, Switzerland). Tris Borate EDTA (TBE) 
electrophoresis buffer (Appendix 2.3) was used.  
 
A molecular weight marker, GeneRuler 100 base-pair (bp) molecular weight 
marker (Fermentas, USA), was loaded in the first lane to ensure the PCR products 












DNA bands were detected in the gel by the addition of Sybr Gold (Molecular 
Probes Invitrogen, USA) to the loading dye (Appendix 2.1) in order to obtain a 
working concentration of 0.04µg/ µl. This mixture was thoroughly vortexed and 
kept in the dark.  
 
Sybr Gold (Molecular Probes Invitrogen, USA) intercalates between bases in the 
DNA molecule and as it is fluorescent, it can be easily detected with a 
transilluminator. However, due to the intercalation of the molecule into the DNA, 
migration of the amplicon will be distorted. As a result the fragments may migrate 
slower through the porous gels and seem larger than expected.  Appendix 2.4. 
shows the Sybr Gold staining procedure. 
 
Fragments obtained from preliminary experiments (integrity of cohort and 
temperature gradient) were detected by the use of Ethidium Bromide (EtBr) 
(Sigma, USA). The fluorescent dye EtBr was directly added during the preparation 
of the agarose gel (Appendix 2.5) to a final concentration of 0.25 milligrams (mg)/ 
milliliter (ml). The dye intercalates between base-pairs in the DNA molecule 
(Sambrook et al.  1989).  
 
Agarose gels were electrophoresed at 160V for at least 30 minutes before 
visualization. The fragments were detected with the UviPro UviGold 
Transilluminator (Whitehead Scientific, USA).  
 
2.2.6. Restriction Enzyme digestion  
 
The hMLH1 c.-93G>A variant in the promoter region of the hMLH1 gene was 











was used to find the possible restriction endonuclease sites. Webcutter is an 
online service (URL: http://ma.lungberg.gu.se/cgi-bin/cutter2).  An example of the 
output of the program can be found in the Appendix 4.  
 
The restriction enzyme PvuII, isolated from the bacterium Proteus vulgaris, 
recognizes the site 5’ CAGCTG 3’ on a DNA sequence. Cleavage by the enzyme 
occurs in the middle of the site, between the G and C residues. The recognition 
site, present in the sequence of interest, is destroyed by the polymorphism 
investigated in this study. As a result, there is no cleavage of the sequence by the 
enzyme. The resulting products can be seen in Table 5.    
 
PCR products were checked for amplification prior to digestion using a 1% 
agarose gel. A fifth of the PCR product together with 3µl of loading buffer 
(Appendix 2.1) was loaded and the gel was electrophoresed at 160V for 30 
minutes. DNA was detected with Sybr Gold (Molecular Probes Invitrogen, USA) 
and AGE was performed; unless otherwise stated.  
 
Preceding digestion of amplified DNA in the entire cohort, the function of the 
enzyme was tested on control samples of known cutting or non-cutting status.  A 
standard digestion reaction consisted of 10µl PCR product, 1 x Buffer 
(corresponding to the enzyme used), 1 U of enzyme PvuII (Fermentas) and made 
up to a final volume of 20µl with distilled water (Sabex); unless otherwise stated. 
Digestion reactions were incubated overnight at 37°C. Post incubation; the 













Table 5:  Fragments expected in the restriction endonuclease (RE) digestion 
 
 
2.2.7. Direct sequencing  
 
Control samples utilized in the optimization procedures for the PCR and detection 
of the hMLH1 promoter variant were of known status. The samples were amplified 
and then verified by direct sequencing. An automated version of the dideoxy-
terminator method of sequencing (originally described by Sanger et al.  1977) was 
used.  
 
Following PCR and AGE, the fragment was analysed and cycle sequencing was 
performed on the Perkin Elmer (Applied Biosystems, USA). The brightness of the 
DNA fragment in the agarose gel determined the amount of DNA to use in the 
cycle sequencing reaction: bright DNA bands correlated with 3µl for the 
sequencing reaction whereas faint DNA bands produced readable sequences with 
5µl. Contents of the cycle sequencing reaction were as follows:  1 x terminator mix 
(Applied Biosystems, USA), less than 3.2µM of one of the primers, 3µl DNA, 1 x 
dilution buffer (Applied Biosystems, USA) and distilled water (Sabex) to a final 
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volume of 20µl.  The standard cycling reaction involved a single denaturing cycle 
at 98°C for 5 minutes followed by 25 cycles of 95°C for 15 seconds,  50°C for 10 
seconds and a final step of 60°C for four minutes. 
 
Following cycle sequencing, the reaction was cleaned by Ethanol precipitation. 
The products of the cycle sequencing reaction were transferred to a 150µl 
Eppendorf microfuge tube. Two microlitres of Sodium acetate (3mM pH 5.5) and 
50ul of 100% ethanol were added to the eppendorf. The solution was mixed well 
and incubated overnight at 4°C. Post incubation, the sample was centrifuged for 
10 minutes at 10000 revolutions per minute (rpm). The supernatant was removed 
and 50ul of 70% ethanol was added to resuspend the pellet. The sample was 
centrifuged again for 10 minutes at 10000rpm and the supernatant was removed. 
The pellet was air-dried for 3 hours and then resuspended in Hi-Di™ Formamide 
(Applied Biosystems, UK ). Samples were placed on the ABI Prism 3100 Gene 
Analyzer (Applied Biosystems, USA) and automated electrophoresis commenced. 
The 3100 Data Collection Software Version 1.1(Applied Biosystems, USA) was 
used to analyze the results of the sequencing reaction.  
 
2.2.8. Statistical analysis  
 
The mutation positive group (cases) and the mutation negative group (controls) 
were subdivided into affection status (“affected with cancer” and “unaffected 
(cancer-free)”) and gender. On examining the cohort by ethnicity, it was found that 
other than mixed ancestry, alternate ethnic groups made up a small proportion. 
Subsequently ethnic division was not applied.  
 
All statistical tests were performed in Microsoft Excel (XP) and MedCalc. The odds 











possible. The Fisher’s Exact test was also performed. Statistical results lower than 
or equal to p = 0.005 was considered as significant.  
 
2.3 Results 
2.3.1. Cohort Analysis  
 
The study consisted of 93 cases (mutation positive individuals) and 97 controls 
(mutation negative individuals). Table 6 below represents a breakdown of the 
cohort into various subgroups. The cases consisted of 38 individuals affected with 
a Lynch associated malignancy (40.9% of the cohort), of which 47.4% (18 
individuals) were female. Of the group of 38 affected mutation-positive individuals, 
37 were of mixed ancestry.  
 
In the control cohort, a total of 77 individuals were affected with a Lynch-
associated malignancy (79.4%). With regard to affection status in the control 
cohort, 38 females (49.4%) were present. With regard to ethnicity, 62.3% (48 
individuals) of were of mixed ancestry. Eleven individuals were of Black ethnicity, 














Table 6:  Cohort stratification 
 
STATUS NUMBER OF INDIVIDUALS 
CASES: MUTATION POSITIVE (C1528T) INDIVIDUALS 93 
AFFECTED WITH CANCER 38 
MALE 20  
FEMALE 18  
BLACK 1  
CAUCASIAN 0  
MIXED ANCESTRY 37  
UNCLASSIFIED   
 
NOT AFFECTED WITH CANCER 55 
MALE 21  
FEMALE 34  
BLACK 0  
CAUCASIAN 1  
MIXED ANCESTRY 54  
UNCLASSIFIED   
CONTROLS: MUTATION NEGATIVE INDIVIDUALS 97 
AFFECTED WITH CANCER 77 
MALE 39  
FEMALE 38  
BLACK 11  
CAUCASIAN 9  
MIXED ANCESTRY 48  
UNCLASSIFIED 9  
 
NOT AFFECTED WITH CANCER 20 
MALE 7  
FEMALE 13  
BLACK 1  
CAUCASIAN 6  
MIXED ANCESTRY 10  











2.3.2. Integrity gel  
 
Prior to amplification and digestion of the DNA obtained from the cohort, the 
concentration of the DNA and its integrity was assessed. DNA with a concentration 
of 100 ng/ µl was utilised.  
 
 
Figure 4:  AGE of the integrity of DNA samples DNA samples resolved on a 1% (w/v) 
agarose gel. The gel was electrophoresed at 160V for 30 minutes. The 
detection agent was ethidium bromide. Lanes 1 - 11: DNA Samples  
 
Figure 4 shows the integrity of a selected series of samples in the cohort. Lanes 1 
and 6 shows no evidence of a DNA band. The samples electrophoresed in Lanes 
2, 3, 5, 7, 8, 9 and 10, though the DNA is faint, show good integrity as a single 
band of is visible at the top of the well. Lane 4 shows fragmented DNA and this 
sample may not be viable for the study. Lane 11 shows DNA with very good 
integrity.  
 
2.3.3. Temperature gradient  
 
As a primary optimization step, a temperature gradient was performed on a control 











calculated primer melting temperatures, were chosen (50°C – 61°C) and the 
presence or absence of the correct sized product was observed.  
 
 
Figure 5:  AGE of the hMLH1 temperature gradient resolved on a 1% (w/v) agarose gel. 
The gel was electrophoresed at 160 volts for 45 minutes. The detection agent 
was ethidium bromide. Lane 1: 100bp GeneRuler Molecular weight marker 
(Fermentas, USA). Lanes 2 – 13: PCR products from annealing temperatures 
50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 and 61°C, respectively. 
 
As observed in Figure 5 above, the fragment is adequately amplified at every 
annealing temperature. No non-specificity of the PCR was noted and no primer 
dimers were visible. The annealing temperature eventually used was 57°C, 
corresponding to Lane 9 in Figure 5.  
 
2.3.4. Restriction Endonuclease digestion  
 
In order to detect the SNP in the promoter region of the hMLH1 gene, restriction 
endonuclease (RE) digestion was used. The G>A polymorphism at -93bp from the 
transcription start site destroys a PvuII recognition site.  
 
Following amplification of the cohort and digestion of the amplicons with PvuII 
overnight at 37°C, resulting products were resolved by AGE. An example of the 












Figure 6:  AGE of restriction endonuclease digestion of hMLH1 on a 3% (w/v) agarose 
gel. Products were detected with Sybr Gold. Electrophoresis was performed 
at 160V for 90 minutes. MWM: 100bp GeneRuler Molecular weight marker 
(Fermentas, USA). U: Uncut sample. Lanes 1 – 7: Digested samples.  
 
A number of heterozygous individuals were identified in Figure 6. Lanes 2, 4 – 6 
showed the digested bands of the PCR product therefore reflecting heterozygous 
individuals. The enzyme can only cleave the wild type sequence and thus results 
in half the fragment being cleaved while the other half not. The remaining 
individuals are wild type due to the presence of a cut sample. Lane 1 represents 
an uncut sample. This sample serves as a reference of the amplified sample at 
340bp. Lanes 1, 3 and 7 represent homozygous variant samples seeing that both 
alleles have been cleaved.  
 
2.3.5. Distribution of Genotypes and Alleles within the study 
cohorts 
 











Table 7:  hMLH1 promoter genotypes in the cohort under investigation 
 






 GG GA AA  
MUTATION POSITIVE              93 
AFFECTED 33 5 0 38 
MALE 17 3 0 20 
FEMALE 16 2 0 18 
UNAFFECTED 43 10 2 55 
MALE 16 4 1 21 
FEMALE 27 6 1 34 
TOTAL 76 15 2 93 
MUTATION NEGATIVE 97 
AFFECTED 43 31 3 77 
MALE 20 18 1 39 
FEMALE 23 13 2 38 
UNAFFECTED 13 5 2 20 
MALE 5 0 2 7 
FEMALE 8 5 0 13 
TOTAL 56 36 5 97 
 
 
2.3.6. Statistical Analysis  
 
To test for any association between site of cancer and the hMLH1 promoter 
genotype, the OR and RR of the heterozygous and homozygous variant 
genotypes were calculated. Significance was calculated by the Fisher exact test 
(MedCalc). Table 8 below shows the results of the site of cancer statistical 












































































































































































































































































































































































































































































































Figure 7:  Graphical representation of the distribution of the genotypes within the 



















Figure 8:  Graphical representation of the distribution of the genotypes within the 












The age of onset was also assessed in the cohorts. The results of the age 
stratification can be observed in Figures 7 and 8.  As observed in Figure 7, within 
the mutation positive affected cohort, no homozygous variant genotype was 
evident. A large proportion of the cases fell between the age groups of 30y and 
50y. Typical age of onset for Lynch syndrome patients is between 35y and 45y 
(Lynch and De La Chapelle, 2003) and the cohort data corresponds to this. There 
are only a few heterozygous genotypes evident in the case cohort. In comparison, 
Figure 8 shows the number of patients with heterozygous genotypes outnumbers 
the homozygous wild type genotypes in the 40 – 49 age group in the mutation 
negative cohort. There are also two homozygous variant genotypes present in this 
age group.  
 
2.4 Discussion  
 
The aim of this study was to ascertain whether or not a SNP in the promoter of the 
hMLH1 gene was associated with the site of malignancy in a control cohort and a 
cohort of individuals predisposed to Lynch syndrome. In addition, an analysis of 
the age of onset of the cohort was also assessed with respect to their hMLH1 
promoter genotype. The polymorphism was detected with the cohorts by restriction 
enzyme digestion, which followed successful amplification of the hMLH1 product.  
 
Lynch syndrome is phenotypically heterogenous – however, there is no molecular 
basis for the tumour spectrum. In light of this, the molecular pathology of each of 
the tumour sites and corresponding germline features are being investigated and 
follow in the next chapter. However, the effects of modifying genes are not to be 
ignored. As a result, the hMLH1 promoter – implicated in recent studies (Harley et 











colorectal, endometrial or ovarian cancer – was investigated in our cohort as a 
potential modifier of site of cancer.  
 
Due to the small sampling size of our cohort and the rigid inclusion methods (only 
individuals with a specific hMLH1 mutation was chosen for the case cohort), only 
colorectal and gynaecologic cancers (namely endometrial and ovarian) were 
prevalent in both the cases and controls. The mutation positive cases did contain 
two breast carcinomas, a renal carcinoma and a skin malignancy. Statistical 
analyses could not be performed on the endometrial and “other” sites of cancer as 
none of these malignancies were present in the mutation negative cohort (Table 
8.). The heterozygous genotype and homozygous genotypes were pooled for all 
statistical analysis due to small numbers.  
 
As the site of malignancy, colorectal cancer has the highest number of affected 
individuals, in both the cases and controls. This is due to the fact that most of 
these individuals are probands and have been initially recruited into the program 
for DNA MMR gene screening.  
 
Due to the skewed data, the OR for the wild type genotype (GG) and the 
occurrence of colorectal cancer is 11.0698 (95% CI: 2.46 – 49.78; p = 0.000181). 
The statistics imply that mutation positive individuals homozygous genotype (GG) 
are at an 11 times increased risk of colorectal cancer. However, it is known the 
mutation positive individuals are already predisposed to this type of cancer and 
this may therefore create a bias toward the mutation positive individuals. Though 
the result reached significance, the sample numbers are too small to justify the 
result and larger study cohorts are required. In addition, there is a large 












In contrast, the RR (the relative risk of carrying the GG and having colorectal 
cancer in the cases (mutation positive group) compared to the controls (mutation 
negative group) is 1.2028 (95%CI: 0.8471 – 1.7079). This indicates that the 
mutation positive group is 1.2 times more likely not to develop a malignancy when 
compared to the case cohort.  
 
The protective effect of the SNP has not been described. Functional studies, 
previously performed on the hMLH1 gene, have placed the SNP within the 
promoter region (Ito et al.  1999). The promoter region is crucial for effective 
transcription of the gene and is it hypothesized that the c.-93G>A SNP may 
dysregulate transcriptional activity of the gene. In addition, the SNP is located 
within a CpG island (Deng et al.  2001), which is commonly methylated in 
sporadic, microsatellite unstable cancers. It may therefore be possible that the 
SNP may “protect” the control group, as shown in the no-cancer statistic, by 
preventing methylation of the site resulting in legitimate transcription of the gene.  
 
Previous studies (Beiner et al.  2006; Raptis et al.  2007; Harley et al.  2008) have 
reported an association between the hMLH1 promoter polymorphism G>A, at 
position -93, and an increased risk in either the development of ovarian or 
colorectal cancer in the general population. As a result, these studies disprove the 
hypothesis of the protective effect of the SNP; though a larger cohort should be 
assessed for clarification of the results observed in this study.  
 
As mentioned previously, the observed results may be due to a number of limiting 
factors such as bias in the cohort selection, small sample sizes and lack of follow-
up in the mutation negative cohorts (specifically due to the age of onset). These 












2.4.1. Limitations of the study 
 
All individuals screened in the study were randomly chosen. The only basis for 
selection was positive confirmation of the C1528T mutation in the hMLH1 gene for 
the mutation positive individuals and no known germline mutation in the DNA 
MMR genes, hMLH1, hMSH2 and hMSH6, despite intensive screening.  
 
A bias is evident in the mutation negative cohort as there are a larger proportion of 
affected individuals when compared to the mutation positive cohort. The mutation 
positive cohort consists of not only the proband, who is usually affected, but also 
family members, as yet unaffected but who have been shown to have the 
predisposing mutation.  
 
In contrast, the mutation negative cohort consists of patients with a Lynch 
associated cancer and in most cases an early onset of disease – in some cases, 
family members have been recruited for the <50y study. However, on molecular 
investigation, no Lynch syndrome predisposing mutation has been found.  
 
The age of onset of affected individuals were taken at age of diagnosis. For those 
unaffected, the age was calculated to date. For mutation positive individuals, this 
method of calculating the current age was adequate as these individuals routinely 
undergo surveillance. However, the surveillance program may introduce a bias in 
the study as it may potentially delay age of onset of a malignancy. In mutation 
negative individuals, this method may introduce a bias in the study as these 
individuals do not undergo the surveillance programs and therefore current 












Only primary malignancies were regarded in the analyses of the study. Metastases 
and secondary malignancies were ignored.  
 
The statistical tests were performed as though the individuals in each group were 
unrelated. However, some of the individuals are blood relatives. Therefore, more 
stringent statistical tests should have been applied taking the Identity by Descent 
(IBD) of some of the individuals into account. However, due to the lack of 
significance of the study, IBD statistics did not need to be applied.   
 
2.4.2. Future prospects 
 
A large, multicentre, national study would ideally be performed in order to obtain 
clearer results as to the effect of the SNP in the general population, as well as 
those already predisposed to Lynch syndrome.  
 
Harley et al.  (2008), Raptis et al.   (2007) and Beiner et al.  (2006) have 
performed such studies and successfully shown an increased risk of various 
malignancies in thos  carrying the polymorphism in the general population. This 
knowledge is of great importance as it provides a guideline to those individuals 
carrying the variant in terms of screening and management programmes therefore 












Elucidation of a genetic signature 
 
3.1. Introduction  
 
Pathologically colonic and extracolonic tumours arising in Lynch syndrome 
patients are similar. These tumours are poorly differentiated, have a large number 
of tumour infiltrating lymphocytes and signet-cell features (Jass 2007). 
Molecularly, in individuals with a predisposing mutation in one of the DNA MMR 
genes, acquisition of a second hit to that gene is hypothesized to result in the 
initiation and subsequently the progression of malignancy at the site at which the 
second hit was acquired (Knudson 1971;  Chao and Lipkin 2006).  
 
The tumourigenic process occurs via the mutator pathway, discussed previously in 
Section 1.4.1. In essence, the study assesses the molecular hallmarks of Lynch – 
associated malignancies. To investigate whether the spectrum of extracolonic 
cancers in Lynch syndrome are a direct result of the DNA MMR deficiency, the 
mutation profile of these cancers was assessed. The working hypothesis of the 
study assumed that should all malignancies be initially generated from the mutator 
pathway, resulting tumours ought to demonstrate the same genetic signature, 
regardless of the site of cancer.  
 
Microsatellite Rich Panel of Genes 
 
The instability of repeated sequences in Lynch syndrome, due to the mutator 
pathway, is well documented.  Numerous studies have focused on the volatility of 











al.  2001, Miyaki et al.  2001, Duval et al.  2002, Vilkki et al.  2002, Woerner et al.  
2005, Jung et al.   2006, Bertholon et al.  2006).   
 
It is imperative to distinguish between target mutations (occurring at the second 
level of the mutator pathway) and passenger mutations (those mutations which do 
not directly contribute to the carcinogenic phenotype). Five criteria used in order to 
define target genes were proposed at a Bethesda Consensus Meeting in 1997. 
The criteria for the genes state that: the genes should have a high rate of 
frequency, biallelic inactivation, a role in the suppressor pathway, the occurrence 
of alterations within the same pathway in MSI-negative tumours and functional 
data (Boland et al. 1998).  
 
To date, there are no official genes adhering to these criteria, though there are 
certain genes which appear to be mut ted at a higher frequency in Lynch 
associated malignancies than in their sporadic counterparts. For example, the 
Transforming growth factor receptor type 2 gene (TGFBR2), the Bcl-apoptosis 
related protein X (BAX) gene, the phospotensin homolog (PTEN), as well as the 
DNA MMR genes hMSH3 and hMSH6 have all been implicated in the mutator 
pathway (Zhou et al.  2002, Fernandez-Peralta et al.  2005), though the exact 
sequence of the mutation pathway is yet to be elucidated.     
 
Miyaki et al.  (2001) examined 29 MSI-H colorectal cancers from Lynch syndrome 
patients for alterations of microsatellites in a number of genes. The study, 
analysing different pathological stages of the tumours, concluded that the number 
of altered genes increased as the tumour progressed through malignancy and that 
alterations upstream of the gene was also evident (Miyaki et al.  2001).  Both 
Duval et al. (2002) and Woerner et al.  (2005) utilised statistical algorithms to 
select for target genes somatically mutated in Lynch syndrome. Somatically 











Duval et al.  (2002), though the authors have stated there are a few genes 
commonly altered. Woerner et al.  (2005) utilised the Selective Target Gene 
algorithm, developed by the authors, to obtain 26 microsatellites occurring within 
coding regions of genes (this is known as coding microsatellites (cMS)). Through 
examination of MSI-H colorectal cancers, the authors found an increase of target 
gene mutations through the evolution of the malignancy from an adenoma to a 
carcinoma. Mutations within certain genes, such as BAX and TGFBR2, showed 
instability at early stages of tumourigenesis while others (for example PTHL3) 
showed instability more frequently in carcinomas (Woerner et al.  2005). These 
studies have attempted to classify the sequence of mutations within the mutator 
pathway. It is evident from these studies that MSI is prevalent in Lynch-associated 
cancers however exact gene mutations are still elusive. The aim of this study is to 
find a consensus in genes commonly mutated in order to obtain a genetic 
signature of Lynch – associated tumours. Elucidation of the genetic signature will 
provide information on the nature of the tumour which will in turn be useful in 
diagnosis, treatment and management.  
 
The presence and degree of MSI in tumour tissue is currently assessed by means 
of testing via the Bethesda panel of markers. The Bethesda panel is a range of 
five highly polymorphic markers. These markers encompass two mononucleotide 
and three dinucleotide repeats, have been internationally utilised since its 
recommendation by the National Cancer Institute in 1977 (Murphy et al.  2006).  
 
Methylation Specific Multiplex Ligation – Dependent Probe 
Amplification (MS - MLPA) 
 
Ms-MLPA was first described in 2005 by Nygren et al.  (2005).  An overview of the 











described utilising DNA isolated from paraffin-embedded/ formalin-fixed tumour 
tissue (Henken et al.  2007). In addition, the original MLPA technique is accepted 
as a simple and reliable method of detection of changes within DNA sequences 
(copy number changes, deletions and insertions) for DNA derived from blood, 
amniotic fluid (Nygren et al.  2005). An advantage of the Ms-MLPA is that in 
addition to the methylation status of the sample, copy number changes can also 
be recorded. Together, the methylation status and the copy number changes may 
prove informative for prognostic results and further management of the patient. 
 
Promoter methylation of 26 tumour suppressor genes is examined in the Ms-
MLPA kit. Worsham et al.  (2006)  and Henkel et al.  (2007) successfully utilised 
the Ms-MLPA technique to identify genes targeted in cervical and head and neck 
squamous cell carcinomas respectively. Epigenetic changes, such as methylation 
of promoters, of tumour suppressor genes results in silencing of that gene. As a 
result, the cell checkpoint mechanisms are compromised hence providing a 
suitable environment for tumourigenesis.  
 
The possible elucidation of the genetic signature is the goal of this chapter. Both 
germline DNA and corresponding tumour material will be assessed to provide both 
inter- and intra- sample analysis. Two methods are utilised to obtain a genetic 
signature; namely, the stability of a panel of microsatellite rich genes Methylation 












3.2. Materials and Methods 
3.2.1. Cohort selection  
 
The cohort for the study was selected from the Colorectal Cancer Database 
housed in the Division of Human Genetics, at UCT. As a pre-requisite for inclusion 
into this study, patients had to be predisposed to Lynch syndrome with the founder 
C1528T mutation in the hMLH1 gene. Additional criteria for inclusion into the study 
were: that the patient be affected with a Lynch syndrome-associated cancer, of 
which the pathological grading be Dukes stage B. Patient consent was granted for 
the use of biological samples by every patient.   
 
3.2.2. Selection of microsatellite rich genes 
 
For a thorough elucidation of microsatellite genes, initially literature was mined. 
Microsatellite sequences that have been implicated as mutational targets in a 
number of published reports were noted (Duval et al.  2001; Miyaki et al.  2001; 
Duval et al.  2002; Vikki et al.  2002; Woerner et al.  2005; Jung et al.   2006; 
Bertholon et al.  2006).  
 
The genes obtained from the published studies were then interrogated. The type 
of repeat (mononucleotide, dinucleotide and trinucleotide), function of the gene 
product (and biological pathways) and observed mutations were identified.  
 
Thereafter, a bioinformatic tool, SUSPECTS 
(http://www.genetics.med.ed.ac.uk/suspects/), was employed to determine lists of 
genes common in Lynch syndrome and in sporadic forms of its extracolonic 











identified from the literature was compared. The SUSPECTS program selects 
genes by scoring each gene according to expression libraries and Gene Ontology 
by relating them to the disease of interest.  Microsatellite rich genes were included 
in the study if the genes were found to be implicated in Lynch syndrome and its 
extracolonic manifestations as well as its functional process.  
 
3.2.3. DNA Isolation  
 
3.2.3.1. Germline DNA 
DNA was isolated from peripheral blood lymphocytes, as described in Chapter 2, 
Section 2.2.2.  
 
3.2.3.2. Formalin-fixed paraffin embedded tumour tissue  
Sections of archived tumour material were obtained from the Department of 
Anatomical Pathology (UCT). Requested tumour material was received as 5 µm 
sections. A haematoxylin and eosin stain accompanied each slide. The Roche 
High Pure PCR Template Preparation Kit (Roche, Switzerland) was employed in 
the isolation of DNA from formalin fixed, paraffin embedded tumour tissue. A few 
amendments were made to the original protocol, supplied by the manufacturer. 
These will be further described below.  
 
Initially, each slide was soaked in 100% xylol (Roche, Switzerland) for 45 minutes, 
to deparaffinise the slide. The tissue section was then submerged in a series of 
varied ethanol concentrations for 10 seconds each, in order to dehydrate the 
tissue. Dehydration was carried out in a stepwise fashion with 100% ethanol 











Finally, the tissue section was submerged in double distilled water to ensure 
rehydration of the material.  
 
The tumour material was then scraped off the slide with a razor blade. The 
material was placed in a 1.5ml microcentrifuge tube. Tissue lysis buffer (100µl) 
(Roche, Switzerland) and Proteinase K (20µl)  (Roche, Switxerland) were added to 
the tissue followed by vortexing and incubation at 37°C for at least eight hours.  
 
Subsequently, 10µl of Proteinase K was added to the microcentrifuge tube and the 
sample was incubated at 55°C for at least one hour.  A volume of 100µl binding 
buffer  (Roche, Switzerland) was then added to the sample and vortexed followed 
by incubation at 72°C for 10 minutes.  Thereafter, 50µl of isopropanol (Merck, 
Germany) was added to the sample and thoroughly mixed. The sample was then 
pipetted into the upper reservoir of a High Pure filter collection tube (Roche, 
Switzerland) and subsequently centrifuged for one minute at 8000 rpm. The 
collection tube, with the flow through was then discarded and the filter tube was 
combined with a new collection tube.   
 
A volume of 250µl Inhibitor removal buffer (Roche, Switzerland) was added to the 
upper reservoir of the filter tube and the sample was centrifuged at 8000 rpm for 
one minute. The filter tube was placed in a new collection tube to which 250µl of 
the Wash buffer was added to the filter tube. The sample was centrifuged at 8000 
rpm for one minute. The collection tube and flow through was discarded and the 
Wash buffer step was repeated and the collection tube was retained. The filter 
tube and collection tube were centrifuged for ten seconds at maximum speed to 
remove the residual Wash buffer from the filter tube. The collection tube was then 
discarded and the filter tube was inserted in to a clean 1.5ml tube.  Elution buffer 











subsequently centrifuged at 8000 rpm for 1 minute.  The eluent was stored at 4°C 
until further use.  
 
3.2.4. Primer design and Polymerase Chain Reaction (PCR) 
3.2.4.1. Multiplex PCR 
 
Multiplex PCR involves the simultaneous resolution of multiple fragments, of 
differing length DNA. Primers amplifying different regions of the genome are 
added to the reaction mix and thus different regions are amplified. These primers 
were designed and analysed via the programs mentioned above (Section 2.2.3).  
 
The freeware, web-based program Autodimer 
(http://www.cstl.nist.gov/div831/strbase/AutoDimerHomepage/AutoDimerProgram
Homepage.htm) was utilised in order to determine the compatibility of the primer 
pairs in a multiplex reaction. Secondary structures of the primers (hairpins, 
homodimers and heterodimer formations) were analysed with Autodimer. The core 
was decreased from seven to three, in order to increase the stringency of analysis. 
All other default parameters were applied. Further information regarding these 
primers can be seen in Table 9.   
 
Primers were ordered from the Department of Molecular and Cell Biology (UCT). 
The forward primer of each gene was tagged fluorescently, either with a Hex or 
Fam molecule.  The fluorescent markers on the primers allowed for automated 
electrophoresis of the PCR products. All reactions were performed on the PX2 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 11:  Components of the PCR reaction 
 
REAGENT CONCENTRATION 
Gene 1: Forward Primer 20uM 
Gene 1: Reverse Primer 20uM 
dNTPs 200uM 
Buffer 1 x 
Taq 1 U 
DNA 100ng/ul 
dH2O Up to 25ul 
 
Three multiplex PCRs were performed. Multiplex 1 contained the following genes: 
AVCR2, hMSH6, AR, CASP5 and IGF2R. Multiplex 2 contained TGFBR2, MBD4, 
hMSH3, PTEN, TAF1b and  Erβ . The final multiplex reaction contained the genes 
TP53, Erα and BAX.  The components of a standard PCR can be seen in Table 
10. Additional primer pairs for the genes were added to the reaction mix and the 
final amount of distilled water (SABAX) was adjusted accordingly.  
 
The cycling conditions for the multiplex reactions were as follows: an initial 
denaturation step at 95°C for 5 minutes; 35 cycles of: 95°C for 30 seconds, 
annealing temperature for 30 seconds, 72°C for 40 seconds. Finally an extension 
period of 72°C for 7 minutes completed the reaction. The annealing temperature of 
each multiplex reaction was unique. Multiplex 1 had an annealing temperature of 
53°C, Multiplex 2 had an annealing temperature of 49°C and Multiplex 3 had an 












Tumour DNA PCR   
Successful amplification of the tumour samples required additional optimization. 
Briefly, 500ng/µl of tumour DNA per 25µl reaction was utilised in the study. The 
cycling conditions for amplification of tumour DNA were slightly altered. The 
reaction commences with an initial denaturation step at 95°C for 5 minutes; 40 
cycles of: 95°C for 30 seconds, annealing temperature for 30 seconds, 72°C for 40 




In preparation for analysis through the ABI Prism 3100 Genetic Analyser (Applied 
Biosystems, UK), the samples were checked on an agarose gel and diluted one in 
ten if necessary. One microlitre of the sample (either neat or diluted) was placed 
together with 8.6µl Hi-Di™ Formamide (Applied Biosystems, UK) and 0.4µl 
GeneScan™ 500 ROX™ Size Standard (Applied Biosystems, UK) in a microtitre 
plate.  Hi-Di™ Formamide (Applied Biosystems, UK ) stabilises single strands of 
denatured DNA. GeneScan™ 500 ROX™ Size Standard (Applied Biosystems, 
UK) is fluorescently labeled and allows for correct sizing of the DNA fragment (the 
sizing can be found in Appendix 5) .  
 
The samples were then denatured at 95°C for 5 minutes on the Hybaid 
Touchdown thermocycler (Hybaid Limited, UK), and snap-frozen on ice. 
Thereafter, the samples were placed in the ABI Prism 3100 Genetic Analyser, and 
the fragments were resolved by automated fluorescent-based, capillary 
electrophoresis. The Applied Biosystems GeneScan software program was used 
for the electrophoresis and the parameters were as follows: 3100 project, dye set 












The data (FSA output files) were subsequently analysed using the Gene Mapper 
software (Applied Biosystems). Bins were created in the regions of interest, with a 
10 base-pair region on either side of the actual fragment size.  
 
3.2.5. Methylation Specific Multiplex Ligation – Dependent Probe 
Amplification (MS - MLPA) 
 
The Ms-MLPA ME100B kit was purchased from MRC Holland and was performed 
as per the quantification protocol provided (MRC-Holland, Version 09; 2008).  An 
overview of the procedure is provided in Figure 9.  
 
Briefly, there are four parts to the reaction: firstly DNA is denaturated and there is  
hybridisation of the provided SALSA probes, a second stage of ligation and 
digestion, the third stage is a PCR and finally separation of the amplification 
products by automated electrophoresis.  
 
The DNA sample, at a concentration of at least 100ng (germline and tumour DNA) 
(resuspended in distilled water), was heated at 98°C for 10 minutes. Thereafter, 
the samples were allowed to cool at 25°C for two minutes before 3µl of a mixture 
of the SALSA-Probe Mix (1.5µl) and MLPA Buffer (1.5µl) was added to each DNA 
sample. The samples were mixed before incubation at 95°C for one minute and 
60°C for 16 hours in the GeneAmp 500 thermocycler (Applied Biosystems, UK).  
 
Following incubation, DNA samples were brought to room temperature (25°C). 
13µl of the buffer mixture was added to each tube (3µl Ligase buffer and 10µl 
distilled water). This mixture was thoroughly mixed before 10µl of the sample was 
transferred to a second tube, labelled M. Both tubes were incubated at 49°C for a 











buffer B, 8.25µl distilled water, 0.25µl Ligase-65 enzyme) was added to the first 
tube – this served as the copy number test. At the same temperature, 10 µl of the 
ligase-digestion mix (1.5µl Ligase-65 buffer B, 7.75µl distilled water, 0.25µl Ligase-
65 enzyme and 0.5µl HhaI enzyme (Promega R6441, 10/ µl)) was added to the 
tube labelled M. Both tubes were incubated at 49°C for 30 minutes followed by 
98°C for 5 minutes.  
 
The next stage of the Ms-MLPA procedure was PCR. Each DNA sample has two 
reactions within the Ms-MLPA; the copy number test and the methylation test 
(which involves digestion of the sample with HhaI). The PCR buffer mixture (2µl 
SALSA PCR buffer and 13µl distilled water) was added to new tubes (each sample 
has two new tubes). Five microlitres of the MLPA digestion-ligation or the MLPA 
ligation reaction was placed in the tubes with the PCR buffer. The tubes were then 
placed on ice while 5µl of the Polymerase mix (1µl SALSA PCR-Primers, 1µl 
SALSA enzyme dilution buffer, 2.75µl distilled water and 0.25µl SALSA 
Polymerase) was added to each tube. With the addition of the Polymerase mix into 
each tube, the tube was immediately placed in a preheated thermocycler (72°C). 
Once all tubes were placed in the thermocycler, the PCR was started with the 
following cycling conditions: 35 cycles of 95°C for 30 seconds, 60°C for 30 
seconds and 72°C for 60 seconds; 1 cycle of 72°C for 20 minutes.  
 
Following the PCR, samples were placed in the ABI 3100 for automated 
electrophoresis. One microlitre of the sample was placed together with 8.6µl Hi-
Di™ Formamide (Applied Biosystems, UK) and 0.4µl GeneScan™ 500 ROX™ 
Size Standard (Applied Biosystems, UK) (Appendix 5) in a 96-well microtitre plate.  
The samples were then denatured at 95°C for 5 minutes on the Hybaid 
Touchdown thermocycler (Hybaid Limited, UK), and snap-frozen on ice. 














Figure 9:  Diagrammatic overview of the Ms-MLPA procedure, obtained from  
Nygren et al.  (2005). 
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Analysis of results 
Ms-MLPA results were initially analysed and manually curated with GeneMapper 
software (Applied Biosystems, version 3). The sizing of each sample was exported 
from the GeneMapper software (Applied Biosystems, version 3) and input into the 
Coffalyser version 8 (obtained off the MRC-Holland website) for further analysis. 
The Methyaltion Status analysis tab was selected for final results.  
 
3.3. Results 
3.3.1. Cohort selection  
 
Seven samples were finally chosen for the tumour analysis, which is represented 
in the table below (Table 11). For both, colorectal and endometrial carcinomas, a 
minimum of three samples each were selected. A single patient presented with a 
renal carcinoma. All samples had the same predisposing mutation in the hMLH1 
gene and were pathologically graded as Dukes B.  
 
Table 12:  Cohort utilized in the study 
 
DNA  NUMBER SITE 
NPC 77.11ELI Endometrial 
NPC 1.232ELK Endometrial 
NPC 82.2LOU Endometrial 
NPC 1.93JOH Colorectal (Proximal colon) 
NPC 1.52MOR Colorectal (Hepatic flexure) 
NPC 101.1EDI Colorectal (Hepatic flexure) 











3.3.2. DNA Isolation  
 
All DNA obtained for the study were analysed prior to use. For DNA isolated from 
both blood and tumour tissue, the quality of the DNA was examined by 
assessment of the migration of the DNA in an agarose gel. The quantity of the 
DNA was assessed by spectrophotometry.  
 
The quantity and quality of the DNA isolated from the tumour tissue is represented 
in the table below (Table 12). The integrity gel of the DNA isolated from tumour 
tissue can be seen in Figure 10.  
 






NPC 1.232 12.5 1.57 -0.55 
NPC 1.248 188.5 1.86 2.96 
NPC 1.52 37.4 1.66 2.83 
NPC 1.93 162.1 1.81 3.32 
NPC 77.11 29.6 1.76 2.14 
NPC 82.2 69.7 1.76 0.94 
NPC 101.1 38.7 1.78 9.77 
 
Ideally, the concentration of DNA isolated from tumour tissue would be at least 
100ng/ µl. However, due to the preservation of the tumour tissue and loss of very 
small sheared fragments of DNA during isolation, the concentration of these 











which for all samples, barring NPC 1.232, are around 1.8. This indicates that there 
is hardly any protein contamination. Unfortunately, the 260/230 ratio which analysis 
organic solvent contamination, is variable ranging from -0.55 (NPC 1.232) to 9.77 
(NPC 101.1) (Table 12). This indicates that there may be some contamination of 
reagents used in the isolation procedure.  
 
 
Figure 10:  AGE of DNA isolated from tumour tissue. DNA was electrophoresed on a 2% 
(w/v) agarose gel and detected with Sybr Gold. Electrophoresis occurred at 
120V for 30 minutes. Lane 1: NPC 1.232, Lane 2: NPC 1.248, Lane 3: NPC 
1.52, Lane 4: NPC 1.93, Lane 5: NPC 77.11, Lane 6: NPC 82.2, Lane 7: NPC 
101.1 
  
Figure 10 shows the integrity gel of DNA isolated from tumour tissue. All lanes 
show fragmented DNA. This is expected due to the preservation, storage and 
isolation of DNA from the slide. Lanes 1, 5 and 6 show very faint fragments and 
these correspond to very low DNA concentrations (12ng/µl, 29.6ng/µl and 
69.7ng/µl respectively) (Table 12). However, Lanes 3 and 7 corresponds to 
samples NPC 1.52 and NPC 101.1 which have lower concentrations that NPC 
82.2 (Lane 6) yet have brighter smears of DNA. This may possibly due to pipetting 
error whereby not enough sample was placed into the wells of the gel or the 
sample was not properly mixed with the loading dye causing a small amount of the 












3.3.3. Selection of microsatellite rich genes 
 
The genes selected for the study can be seen in Table 13. Information about the 
gene, gene function, the microsatellite under investigation and previous studies on 
the microsatellite are also provided. As previously mentioned, the genes were 
primarily chosen through literature and then subjected to bioinformatic analysis to 
narrow down the list of genes. In total, 14 genes were chosen for analysis. All but 
two of the genes had cMS. One of the genes (Estrogen receptor Alpha) had a 
promoter microsatellite while the other had a microsatellite found in an intron 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To assess the alleles in the 14 microsatellite rich genes of interest, multiplex PCR 
was performed on the samples. Thereafter, the samples were electrophoresed on 
a three percent agarose gel in order to ensure the reaction was successful.  
 
Samples that were correctly amplified were diluted 1/10 if the PCR products were 
too bright. Thereafter, the samples were pooled before 1µl of the sample was 
taken through genotyping.  
 
Results obtained from the genotyping analysis are provided in Table 14. The 
various alleles observed for each gene studied were allocated a numerical 
number. The allele sizes and details are provided in Appendix 6.  Figure 11 
represents sample NPC 1.248 genotyped for the MBD4 gene. As a single peak is 
observed, NPC 1.248 is homozygous. The allele size, 224bp, represents Allele 2.  
 
 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Six of the genes (CASP5, IGF2R, TGFBR2, MSH3, PTEN and TAF1B) under 
investigation, displayed the same genotype in all seven samples. ACVR2, 
highlighted in red, demonstrated a different genotype in the individual who 
presented with renal cancer when compared to the other six samples.  
 
The majority of the genes in the tumour samples remained static. The Erβ gene 
did however show instability in six of the seven samples. An example of the 
instability can be seen in Figure 12.  
  
 
Figure 12:  Example of the instability seen in the Erβ gene for sample NPC 1.232.  
 
 
3.3.5. Methylation Specific Multiplex Ligation – Dependent Probe 
Amplification (MS - MLPA) 
 
The results of the methylation status of each sample and the corresponding 
tumour tissue are tabulated (Table 15). Figure 13 shows the GeneMapper output 











Methylation status of the tumour was established via the ratio of the cut sample to the 
reference (uncut) sample of the Ms-MLPA. The calculations of the ratios were 
automatically performed by the Coffalyser software. The classification of methylation 
was categorised into unmethylated (ratio of less than 0.25), hemi-methylated (ratio of 
between 0.25 and 0.75) and methylated (ratio greater than 0.75).  Table 15 contains 
the ratios of the germline and tumour DNA analysis for each sample.  The table is also 
colour-coded: red represents no methylation, green represents hemi-methylation and 
blue represents homozygous methylation.  
 
The Ms-MLPA kit contains 14 control probes. These probes should be amplified in all 
samples. There are 26 tumour suppressor gene probes in the kit, corresponding to 24 
tumour suppressor genes (two genes, MLH1 and RASSF1 contain two probes). In 
normal, healthy samples these genes should not be methylated (either heterozygous 
methylation or homozygous methylation) and have a ratio of less than 0.25. This can 
be seen from the results obtained from the germline samples of NPC 1.232, NPC 
1.248 NPC 1.52, NPC 82.2 and NPC 101.1 (Table 15). When an allele of the tumour 
suppressor gene is methylated, that allele cannot be digested by the restriction 
enzyme HhaI. As a result, that allele is amplified in the PCR and when the result of the 
cut sample is compared to the reference sample, that gene would have a ratio greater 






























































































































































































































































































































z ---i> -=::: 
" v 
~ 
" ---i> -=== ~ 
0 
-=::: 







~ " ---i> -=c ~ 
" ---i> I V 




v ---i> " e 
" ---i> v 0 
" " ---i> 0 , 
~ ~ ~ 
V , 
---i> > ! ! 
< 
S 
---i> " ~ 
~ ---i> 
" 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4. Discussion  
 
The aim of the study was to determine a genetic signature of Lynch-associated 
malignancies by distinguishing molecular similarities between pathologically 
similar colorectal, endometrial and renal cancers. A panel of microsatellite rich 
genes and Ms-MLPA were the techniques used.  
 
3.4.1. Microsatellite rich genes 
 
Three genes involved in the apoptosis pathway were analysed in the study. These 
genes, BCl-associated protein X (BAX), Caspase 5 (CASP5) and Tumour protein 
53 (TP53) have coding microsatellites, which may deem these genes susceptible 
to microsatellite instability in the presence of defective mismatch repair. However, 
these genes remained static between germline and tumour samples.  
 
Activin receptor type 2A (ACVR2) is a transcriptional regulation gene and also 
involved in the Transforming Growth Factor signalling pathway. This gene contains 
two microsatellite repeats. The specific repeat examined in this project is found in 
exon 10 and is reported to be frequently mutated in colon cancer (Jung et al.  
2006). Deacu et al.  (2004) demonstrated that restoration the ACVR2 gene within 
deficient cell lines allowed the TGFBR2 pathway to be restored. To date, there are 
no reports on the association of the ACVR2 gene and renal cancer. The results of 
the ACVR2 gene showed that the individual who presented with renal cancer had 
an alternate genotype of the gene when compared to the other sex members of 
the cohort. The individual was homozygous for the genotype, of which the product 












The transforming growth factor receptor type 2 (TGFBR2) gene is involved in the 
regulation of growth and proliferation of cells and contains a tract of ten adenine 
bases in exon three of the gene. Expansion and contraction of this tract is noted in 
most microsatellite unstable colorectal cancers (Woerner et al.  2005, Jung et al.  
2006) and is thought to confer a growth advantage to the cancerous cells. There 
are numerous reports which implicate microsatellite instability of the TGFBR2 
gene in Lynch syndrome cancers. Unfortunately, in this study, the TGFBR2 gene 
was found to be stable within the tumour tissue of the genes assessed.  
 
Two DNA MMR genes were assessed and no somatic mutations were observed in 
the tumour tissue. The genes hMSH3 and hMSH6 have coding microsatellites in 
exon eight and five respectively. Both genes have a tract of eight repeats; hMSH3 
has a tract of adenine whereas hMSH6 has a tract of cytosine residues. Expansion 
or contraction of these repeats may lead to impaired function of the gene which in 
turn will lead to impaired DNA repair (Miyaki et al.  2001). Mutations within the 
hMSH6 gene, particularly point mutations, are implicated in Lynch syndrome; 
however, mutations within the gene may lead to a variation in the age of onset of 
the disorder. In addition, hMSH6 mutations have been associated to have an 
increase in the risk of the gynaecologic cancers (Cederquist et al.  2005).  
 
Three steroid hormone genes, the androgen receptor (AR) and the estrogen 
receptors alpha and beta (Era and Erβ), were assessed. The results of the study 
hoped to provide further insight into the tissue specific nature of the extracolonic 
cancer spectrum. Recent publications (Frogatt et al.  1999, Campbell-Thompson 
et al.  2001, Slattery et al.  2006) have found associations between these three 
genes, specifically the length of microsatellite regions within the genes and the 
occurrence of colorectal cancer. In addition, the androgen receptor has also been 












In 2001, Campbell-Thompson et al.  investigated the expression of the estrogen 
receptor subtypes and isoforms in colon tumours, normal colonic mucosa and 
colon cancer cell lines. This study was performed in order to elucidate the 
protective effect of female hormones. In Lynch syndrome, the lifetime risk of 
developing colon cancer is much lower in females than in their male counterparts 
(Froggatt et al.  1999).  The Campell-Thompson et al.  (2001) study and a more 
recent study (Slattery et al.  2005) have shown that the expression of Erβ is 
prominent in the colon and decreased levels of the gene in females are associated 
with colonic malignancies. Six of the seven tumour tissue samples analysed in the 
current study showed instability at this receptor.  Erβ is involved in the regulation 
of gene expression (Deroo and Korach. 2006). It is hypothesised that 
microsatellite instability observed in the Erβ gene may lead to abnormal 
transcriptional activation and erroneously result in the silencing of tumour 
suppressor genes or conversely an increase the transcription of proliferative genes 
(Slattery et al.  2005). MSI evident at this gene in the tumour samples examined 
may be informative as to a potential marker for Lynch-associated malignancies. 
However, this result needs to be validated and an investigation of Erβ in a control 
tumour set (of sporadic malignancies) is required.  
 
The study involving the microsatellite rich genes unfortunately did not prove fruitful 
apart from one gene. The lack of microsatellite instability seen in the panel of 
genes assessed may be due to the stage of the cancer.  All the tumours assessed 
were Dukes Stage 2 cancers and perhaps the rate of instability increases with the 
increased number of mutations randomly introduced into the cancerous tissue. 
Also, tumour tissue is highly heterogeneous and several sections from varying 
tumour position would have been ideally examined. However, previous studies 
(Jung et al.  2006, Vilkki et al.  2002) have successfully uncovered mutations 
within microsatellite rich genes while utilising Dukes stage 2 cancers. A limitation 
to the study was that the tumours were analysed by different pathologists and 
during DNA isolation from tumour tissue, the tumour sample was not micro-













The MS-MLPA was performed in order to potentially identify a defining signature of 
DNA MMR negative malignancies. The Ms-MLPA kit analyses the gene copy 
number and the methylation status of the promoter regions of tumour suppressor 
genes.  
 
Two of the tumour suppressor genes, analysed by the Ms-MLPA kit for promoter 
methylation, were found to be methylated (either hemi-methylation of one allele or 
complete methylation) in all the tumour samples. These genes are HIC1 and 
TIMP3.  
 
The HIC1 gene is also known as the Hyper-methylated in Cancer Protein and 
encodes a transcription factor. Functional interaction of HIC1 with the tumour 
suppressor gene TP53 has been described (Fleuriel et al.  2008). Feng et al.  
(2008) has shown that methylation of four tumour genes; namely HIC1, RASSF1, 
CABIN1 and MINT31; is associated with ovarian carcinoma. Ovarian carcinoma is 
a member of the tumour pectrum of Lynch syndrome unfortunately, there was no 
ovarian tissue malignancy available to analyse in the current study. It was 
observed by Feng et al.  (2008) that methylation of the HIC1 and RASSF1 genes 
occurred early in the evolution of the malignancy.  The tumour tissue analysed in 
this study corresponded to the Dukes B pathological grading and therefore 
correlate with the Feng et al.  (2008) study in terms of the early methylation of 
HIC1.  
 
Joensuu et al.  (2008) investigated the methylation of 24 tumour suppressor genes 
in a cohort of Lynch syndrome patients who presented with either an endometrial 
or colorectal carcinoma. Four tumour suppressor genes, one of which was TIMP3, 











CHD13, APC and GSTP1. Mutations within the tissue inhibitor of metalloproteases 
3 (TIMP3) are known to result in Sorsby fundus dystrophy. Methylation of the gene 
has been implicated in breast, uterine, oesphogeal, pancreatic, renal and 
colorectal carcinomas (Lui et al.  2005, Smith et al.  2008). It is evident methylation 
of TIMP3 is critical in the tumourigenic process however, in studies performed on 
the methylation of TIMP3 in the various malignancies described above; the MMR 
status of each carcinoma was not mentioned. Therefore it is not clear whether 
TIMP3 methylation is common to all malignancies (familial and sporadic) and all 
tumourigenic pathways (Vogelstein and mutator).   
 
NPC 1.248 is the only sample which presented with a renal carcinoma. The 
tumour DNA shows vast methylation of all bar two tumour suppressor gene 
promoters. A control gene, CTNNB1, showed hemi-methylation in the germline 
DNA. The excessive methylation of the tumour DNA may be due vast 
heterogeneity of the tumour tissue and may be a false positive result as the 
tumour section was not micro-dissected prior to isolation. The heterogeneity of the 
tumour section could also have resulted in certain areas of the tumour being a 
pathologically higher grading than Dukes B.  
 
In a number of samples, both tumour and germline, there is hemi-methylation or 
loss of amplification of the control samples. In the tumour DNA, it is possible that 
due to the degradation of DNA during preservation and isolation, these sequences 
of these genes may have been sheared and therefore amplification may have 
been restricted. The germline DNA sample for NPC 77.11 shows no amplification 
of three control probes; BRCA2, MLH3 and BCL2. As the control probes are 
expected to successfully amplify in all samples, especially in germline DNA, the 
lack of amplification of these control probes is unknown. In addition, three germline 
samples (NPC 1.248, NPC 1.93, NPC 77.11) have hemi-methylation of CTNNB1. 
Perhaps the amplification of these control probes were not as successful as the 











probe ratios seemed to fall within the lower ratio categories causing the automated 
program to regard them as either hemi-methylated or not amplified.  
 
Methylation of the tumour samples of the tumour suppressor genes HIC1 and 
TIMP3 gene may provide impetus to further investigate a genetic signature in 
Lynch syndrome tumours. 
 
3.4.3. Future work 
 
Verification of the promoter methylation of HIC1 and TIMP3 in the samples by 
bisulphite sequence is required. Malignancies at different pathological stages 
taken through both the microsatellite panel of genes and the Ms-MLPA may be 
more informative about the tumourigenic process. A setback in the study was the 
ability in obtaining archived tumour material from mutation positive individuals. 
Perhaps, had there been a larger tumour tissue cohort and tumour tissue at 
various stages of tumour development, the results may have been more 
informative. In future, the assessment of these genes may be beneficial when 











Chapter 4: Bioinformatic analysis 
 
4.1. Introduction  
 
This project aims to elucidate the occurrence of extracolonic malignancies in 
Lynch syndrome by focusing on the characterization of tumours from the 
susceptible anatomic sites.   
 
In order to supplement the study, bioinformatic analyses of existing, available 
microarray data was assessed. The aim was to provide further insight into 
potential mechanisms for the initiation of malignancy in the susceptible anatomic 
sites. To date, the identification of candidate genes allowing the proliferation of 
cancerous tissue in only certain anatomic sites have been elusive. 
 
4.2. Materials and Methods 
4.2.1. Overview 
 
Figure 14 represents a diagrammatic overview of the bioinformatics approach. 
First, the ONCOMINE database was accessed and microarray data on 
microsatellite unstable colorectal and endometrial tissue was obtained. The 
common under and over expressed genes in these cancer profiles were acquired. 
Thereafter, the common candidate genes were analysed in isolation and through 






































Microarray data was retrieved from the ONCOMINE database 
(http://www.oncomine.org) (Rhodes et al. 2007). The paper-centric database 
provides data from previously performed and published cancer studies. Initially 
data representing microsatellite status was identified. The studies of interest 
compared the level of gene expression between microsatellite stable tumours and 
those exhibiting MSI. Due to the stringent criteria only three investigations were 
available for study. The studies chosen were; Watanabe et al.  (2006), Koinuma et 
al.  (2004) and Mutter et al.  (2001). Watanabe et al.  (2006) and Koinuma et al.  
(2004) investigated colorectal tissue samples whereas the Mutter et al.  (2001) 
study analysed endometrial samples.  Under-expressed and over-expressed 












4.2.3. Conversion of gene names to Ensembl identifiers 
 
The gene lists exported from the ONCOMINE database were Human Genome 
Nomenclature Committee (HGNC) gene symbols. Prior to analysis, the gene lists 
were converted into Ensembl identifiers by mining the Ensembl site with Biomart. 
The database used for the mining was the Ensembl 50 database with the 
Homosapiens NCBI 36 dataset. Under the filters the gene identifier list was 
selected and the HGNC symbol was chosen. The gene lists obtained from 
ONCOMINE were added to the available section. Thereafter, the results tab was 
selected and the lists of Ensembl identifiers were chosen to be exported via a text 
document.  
 
Upon manual curation of the resulting lists, it was found that there were duplicates. 
The duplicates were therefore removed utilising the Excel Unique and Duplicate 
Remover.  
 
4.2.4. Collation of gene lists and scoring matrix 
 
The gene lists were analysed in Microsoft Excel. A scoring matrix was obtained 
from Dr Tiffin (personal communication). The scoring matrix was written using 




The gene lists from the microarray studies were placed in an Excel document 
containing the scoring matrix. Under-expressed and over-expressed gene lists 











individual columns. The scoring matrix the analysed the list of genes input and 
scored each gene on the number of times the gene appeared in each column list.  
Each gene, for each of the two anatomic sites in question, was weighted equally. 
The results of the scoring matrix were manually curated and genes with a final 
score of three were then selected as commonly expressed in all the three 
anatomic sites.  
 
4.2.5. Automated analysis of common under-expressed and over-
expressed genes 
 
Genes found to be commonly under-expressed or over-expressed in the 
microsatellite unstable colorectal and endometrial tissue were investigated. Initally, 
information regarding the genes was obtained by accessing the Ensembl website. 
Functional annotation of the genes was obtained using the Gene ontologies 
(http://www.geneontologies.org).   
 
Known relationships between the genes were examined by utilising the CHILIBOT 
website (http://www.chilibot.net) (Chen and Sharp 2004). This data-mining 
program identifies the relationships between the genes by extracting information 
via literature. Protein interactions were then interrogated via the web-based 
Search Tool for Retrieval of Interacting Proteins (STRING) (http://string.embl.de) 
(von Mering et al.  2007). Where possible, biological pathways where examined by 
interrogating the Reactome (http://www.reactome.org) (Vastrik et al.  2007) and 













4.3.1. Up and Down regulated genes in ONCOMINE 
 
Three studies from the ONCOMINE database were selected for further study in 
this investigation. Microarray data showing both down-regulated and up-regulated 
genes in tumour tissue comparing microsatellite stable and microsatellite unstable 
status was obtained. Only those genes with a cut-off p – value of 0.05 were 
selected for further analysis. Table 16 shows the results of the selection.  
 














Watanabe Colorectal 51 33 13495 8862 
Koinuma Colorectal 10 10 1639 1437 
Mutter Endometrium 5 5 195 130 
 
4.3.2. Comparison of the ONCOMINE commonly expressed genes.  
 
In total four genes were commonly under-expressed in the colorectal and 
endometrial studies. Three genes were commonly over-expressed. The results 




































































































































































































































































































































































































































































































































































































































































































































































































































There was no relevant literature on the relationships between the four common 
under-expressed genes. In terms of the over-expressed genes, there was only a 




Similarly there were no interactions between the gene products of the under-
expressed genes. There was only a protein interaction between HLA-DOA and 
HLA-DMB in the over-expressed gene cohort, shown in Figure 15. The lines 
linking HLA-DOA and HLA-DMB indicate there is a putative interaction of these 
proteins though an experimental assay has not been performed.  There is no 
evidence of an interaction of the BRD8 protein with HLA-DOA or HLA-DMB.     
 
 
Figure 15:  STRING output of the relationship of the over-expressed genes common to 





Interrogation of the seven gene sequences (NCBI, Ensembl) showed no 











4.4. Discussion  
 
Analysis of existing microarray data from cancer profiles were assessed in order to 
potentially expose novel candidate genes which may explain the occurrence of 
extracolonic malignancies in Lynch syndrome. Gene expressions in Lynch 
syndrome susceptible tissue sites were analysed.   
 
Microarray data was obtained for microsatellite unstable and microsatellite stable 
tumour tissue from both colorectum and endometrium. Comparison of under-
expressed and over-expressed genes in these sites was performed. Genes 
common to both sites were obtained for both under-expression and over-
expression.  The cohort of commonly expressed genes were analysed in terms of 
functional ability, literature mining and protein interactions.  
 
Four genes were found to be commonly under-expressed in the microsatellite 
unstable colorectal and endometrial tissue compared to microsatellite stable 
tumours of those sites. One of the genes, KIAA0240, is yet to be characterised. 
CYP4AII is involved in fatty acid metabolism and iron binding (Table 17). A 
literature search could not find an association between the CYP4AII gene and 
cancer.  
 
MAML1 is mainly involved in the Notch signalling pathway though a MAML1 – 
TP53 interaction has been recently described (Zhou et al.  2007). The authors 
showed the MAML1 protein is a constituent of an activator complex which binds to 
response elements within target genes that are regulated by TP53 (Zhou et al.  
2007).  In addition, Alves-Guerra et al.  (2007) found MAML1 to be part of the Wnt 
signalling pathway and a co-activator of β-catenin. In vivo experiments showed the 
MAML1 protein being recruited by β-catenin for interaction with the cell cycle 











knockdown of MAML1 in colorectal cancer cell lines resulted in cell death. The 
group hypothesised cell death was due to the disruption of β-catenin and the 
failure to recruit cell cycle proliferation proteins CCND1 and c-myc (Alves-Guerra 
et al.  2007).  Under-expression of MAML1 observed in this study can be 
postulated to result in better prognosis seen MSI malignancies. The decreased 
concentration of MAML1 will decrease its interaction with β-catenin and in turn 
decrease CCND1 and c-myc thus slowing down the proliferation process.    
 
Mori et al.  (2004) examined MSI-H colorectal tumours and found that the PTPRU 
gene was frequently methylated in predominantly right-sided malignancies. 
Methylation of the gene has been implicated in pancreatic carcinomas and 
lymphocytic leukaemia (Motiwala et al.  2007). PTPRU was commonly under-
expressed in the current study and this may be attributed to partial methylation of 
the gene in MSI colorectal and endometrial malignancies.   
 
Of the over-expressed genes, the highly polymorphic immune response genes 
HLA-DOA and HLA-DMB are of interest. Lynch syndrome patients are reported to 
have a better prognosis than their sporadic counterparts (Jass 2007). It is 
hypothesised that the better prognosis is a result of the large numbers of tumour 
infiltrating lymphocytes which are a hallmark of the Lynch malignancies.  BRD8 is 
involved in apoptosis and DNA repair (GeneCards 2006). However, in the midst of 
a DNA repair deficient mechanism, the BRD8 protein may be non-functional. 
Assuming the MSI malignancies are due to a DNA MMR deficiency, perhaps the 
over-expression of BRD8 is the cell’s mechanism to try to regulate the DNA repair 
mechanism.   
 
ONCOMINE  
The ONCOMINE site provided a comprehensive set of cancer microarray data. 











under investigation. Unfortunately, a criticism of the site is that spelling errors were 
found to be present and when searching for specific terms, this may lead to a lack 
of results due to the grammatical errors.  
 
Due to the specific nature of the study, only data from microsatellite stable and 
microsatellite unstable colorectal and endometrial tissue was able to be analysed. 
Ideally, all the Lynch susceptible sites would have been analysed. The 
extracolonic tumour spectrum in Lynch syndrome consists of a plethora of 
anatomic sites and more microarray data involving these sites would be useful in a 
study such as this.  This lack of information therefore is a major limitation of the 
study. 
 
Two of the studies investigated (Koinuma et al.  2004, Watanabe et al.  2006) 
examined colorectal tissue. The Watan be et al.  (2006) study had more 
significantly differentially expressed genes than the Koinuma et al.  (2004) study. 
This could be attributed to the larger number of samples utilised in the Watanabe 
et al.  (2006) study. The endometrial tissue study performed by Mutter et al.  
(2001) used an older microarray chip than the colorectal studies. Therefore, 
perhaps a larger cohort of commonly differentially expressed genes may be 
uncovered when the same microarray chip is utilised.  
 
In conclusion, the results of the bioinformatics analyses of the microarray data is 
encouraging though the limitations discussed above should be considered. 
Alternate biological functions and interactions must be taken into account when 











 Chapter 5: Concluding remarks 
 
The aim of the project was to elucidate the occurrence of extracolonic 
malignancies in Lynch syndrome. Numerous techniques were utilised in order to 
attempt to obtain an answer to the study.  
 
5.1. Modifier study  
 
The essence of the project analyses the site of cancer within Lynch syndrome. As 
a result, the effect of modifier genes cannot be discounted. To date, there are no 
studies reporting on the variation in the site of cancer and therefore no potential 
candidate genes.  
 
A promoter variant within the hMLH1 gene has been recently associated with an 
increased risk of endometrial and ovarian cancer within the general population. 
The promoter variant was analysed in this study and was not associated with 
either differing sites of cancer or age of onset within the cohort under investigation.  
It was found that significantly more individuals with an existing mutation in the 
hMLH1 (predisposing Lynch syndrome) (p = 0.000181) were found to be at a 
significantly increase risk for the development of colorectal cancer though there is 
a bias introduced in the study as a result of the DNA MMR existing mutation.  
 
5.2. Genetic signature  
 
It was hypothesized that malignancies originating from the same point, in other 
words from a defective DNA MMR gene and following the same tumourigenic 











signature. In individuals predisposed to Lynch syndrome, genetic material from 
tumour tissue was assessed and compared to its germline DNA to document the 
extent of the alterations within the tumour tissue. Malignancies from various 
anatomic sites were examined in order to elucidate molecular similarities between 
the tumours.  
 
A panel of microsatellite rich genes and Ms-MLPA of tumour suppressor genes 
were utilised. Results of the 14 microsatellite rich genes showed instability of the 
Erβ gene was present in all but one of the tumour samples. The Ms-MLPA profile 
of all tumour samples exhibited methylation of two tumour suppressor genes, HIC1 
and TIMP3. Though the sample size was small and limited to three sites of cancer, 
these putative findings provide impetus for further study into the genetic signature 
of Lynch-associated malignancies.   A study examining the evolution of 
tumourigenesis in Lynch syndrome patients will be beneficial to understanding the 
intricacies of the mutator phenotype. Use of the panel of microsatellite rich genes 
and the Ms-MLPA was valuable in the illumination of a genetic signature, though 
microarray experiments will provide more information.  
 
5.3. In silico analyses  
 
In an attempt to potentially uncover candidate genes for site of cancer, 
bioinformatics analyses were undertaken. The web based cancer profile database, 
ONCOMINE was utilised to gain information on microarray data focusing on 
microsatellite status of colorectal and endometrial tumour tissue. Lists of under-
expressed and over-expressed genes from the microarray study that were 
common to both tissue sites were collated. Four genes (KIAA0240, CYP4AII, 
MAML1, and PTPRU) were commonly found to be under-expressed in 
microsatellite unstable colorectal and endometrial tissue. Three genes (BRD8, 
HLA-DOA, and HLA-DMB) were found to be commonly over-expressed. Though 











endometrial tissue utilised), genomic and proteomic interrogation of these genes 
are required to determine their validity in vivo.  
 
5.4. Final remarks  
 
This study provided insight into the complexity of Lynch syndrome associated 
tumours. Perhaps the promiscuity of the disease may be due to the 
microenvironment and external environmental factors and not the genetic material 
in isolation – as was hypothesized in this project.  
 
The importance of the biological pathways in their inherent environment should 
provide more answers into the susceptibility of certain tissue sites. In addition, 
alternate biological mechanisms, for example the role of the immune and vascular 
systems as well as the effect of carcinogens and lifestyle choices, should be 
thoroughly investigated.  
 
The work undertaken in this project encompassed a plethora of technologies such 
as familiarization with comprehensive and molecular databases, cohort selection, 
genotyping, molecular mutation detection techniques, Ms-MLPA, data analysis 
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 Loading dye  
 
 40% Sucrose solution  
 Bromophenol blue  
 
2.2.  
1% agarose gel (100ml)  
 
 1g agarose  
100ml 1 x TBE  
Heat until the agarose has dissolved.  
When cool, pour into gel tray and allow to set.  
 
2.3.  
10 x TBE  
 
 216g Tris 
 110g Boric acid 
 14.8g EDTA 














Staining with Sybr Gold 
  
Add 2µl of Sybr Gold to 1ml of loading dye  
 Vortex  
 Store in dark when not in use 
 
2.5.  
Staining with Ethidium Bromide  
  
Add 3µl of EtBr per 50ml of agarose gel when cool. 
 Swirl around to incorporate the EtBr into the gel. 














APPENDIX 3  
 
GeneRuler 100bp MOLECULAR WEIGHT MARKER (FERMENTAS, USA)  
 
 Dilute to a working stock of 0.05µg/ µl 

















WEBCUTTER OUTPUT FOR hMLH1 PROMOTER VARIANT:  
hMLH1 wild type 
340 base-pairs 
 
                            Eco57I                     NspBII               
                      NspBII                      SfcI PvuII Eco57I         
gctgtccaatcaatagctgccgctgaagggtggggctggatggcgtaagctacagctgaaggaagaacgtgagca base-pairs 
cgacaggttagttatcgacggcgacttcccaccccgacctaccgcattcgatgtcgacttccttcttgcactcgt 1 to 75 
                      MspA1I                      BstSFI                    
                                                       MspA1I               
                                                                           
     BsiI                                              EcoT14I      Eco64I BbiII 
Alw21I                                                StyI       Ksp632I Hin1I 
AspHI     MslI            Eco57I           XbaI       Eco130I    Eam1104I Msp17I 
cgaggcactgaggtgattggctgaaggcacttccgttgagcatctagacgtttccttggctcttctggcgccaaa base-pairs 
gctccgtgactccactaaccgacttccgtgaaggcaactcgtagatctgcaaaggaaccgagaagaccgcggttt 76 to 150 
Bbv12I                                                ErhI       SapI KasI  
BsiHKAI                                               BssT1I     EarI BshNI 
    BssSI                                                          BanI AccB1I 
  
     EheI                                                                   
    NarI BbeI                                                               
      Bsp143II                                                              
atgtcgttcgtggcaggggttattcggcggctggacgagacagtggtgaaccgcatcgcggcgggggaagttatc base-pairs 
tacagcaagcaccgtccccaataagccgccgacctgctctgtcaccacttggcgtagcgccgcccccttcaatag 151 to 225 
Hsp92I HaeII                                                                
 BsaHI BstH2I                                                               
    AcyI                                                                    
                                                                    AflII   
    EaeI                                                         BanII MspCI 
   NspBII                                                        Eco24I BfrI 
cagcggccagctaatgctatcaaagagatgattgagaactggtacggagggagtcgagccgggctcacttaaggg base-pairs 
gtcgccggtcgattacgatagtttctctactaactcttgaccatgcctccctcagctcggcccgagtgaattccc 226 to 300 
   MspA1I                                                        FriOI Vha464I 











                                                                    Bst98I  
                                                                              
ctacgacttaacgggccgcgtcactcaatggcgcggacac  base-pairs 
gatgctgaattgcccggcgcagtgagttaccgcgcctgtg  301 to 340 
                                                                                   
                                           
 















                            Eco57I                                          
                      NspBII                      SfcI                      
gctgtccaatcaatagctgccgctgaagggtggggctggatggcgtaagctacagctaaaggaagaacgtgagca base-pairs 
cgacaggttagttatcgacggcgacttcccaccccgacctaccgcattcgatgtcgatttccttcttgcactcgt 1 to 75 
                      MspA1I                      BstSFI                    
                                                                            
                                                                            
    BsiI                                              EcoT14I      Eco64I BbiII 
Alw21I                                                StyI       Ksp632I Hin1I 
AspHI     MslI            Eco57I           XbaI       Eco130I    Eam1104I Msp17I 
cgaggcactgaggtgattggctgaaggcacttccgttgagcatctagacgtttccttggctcttctggcgccaaa base-pairs 
gctccgtgactccactaaccgacttccgtgaaggcaactcgtagatctgcaaaggaaccgagaagaccgcggttt 76 to 150 
Bbv12I                                                ErhI       SapI KasI  
BsiHKAI                                               BssT1I     EarI BshNI 
    BssSI                                                          BanI AccB1I 
  
     EheI                                                                   
    NarI BbeI                                                               
      Bsp143II                                                              
atgtcgttcgtggcaggggttattcggcggctggacgagacagtggtgaaccgcatcgcggcgggggaagttatc base-pairs 
tacagcaagcaccgtccccaataagccgccgacctgctctgtcaccacttggcgtagcgccgcccccttcaatag 151 to 225 
Hsp92I HaeII                                                                
 BsaHI BstH2I                                                               
    AcyI                                                                    
                                                                     AflII   
    EaeI                                                         BanII MspCI 
   NspBII                                                        Eco24I BfrI 
cagcggccagctaatgctatcaaagagatgattgagaactggtacggagggagtcgagccgggctcacttaaggg base-pairs 
gtcgccggtcgattacgatagtttctctactaactcttgaccatgcctccctcagctcggcccgagtgaattccc 226 to 300 
   MspA1I                                                        FriOI Vha464I 
    CfrI                                                            BspTI   











                                           
                                           
ctacgacttaacgggccgcgtcactcaatggcgcggacac  base-pairs 
gatgctgaattgcccggcgcagtgagttaccgcgcctgtg  301 to 340 
                                           
                                                                                  
 
The following endonucleases were selected but don't cut this sequence: 








































Allele 1 Allele 2 Allele 3 Allele 4 Allele 5 
ACVR2 A 8 112 100 112    
 Erβ  CA  159 153 157 159 161 165 
MSH6 C 8 202 200 201    
AR CAG  255 225 231 237 245 256 
CASP5 A 10 322 321     
IGF2R G 8 352 350     
TP53 A 11 443 441 442    
BAX G 8 113 106 108 114 119  
TGFBR2 A 10 174 165     
MBD4 A 10 226 223 224    
MSH3 A 8 321 320     
PTEN A 6 345 347     
ERa TA  384 376 392 394 396  
TAF1B   451 441 442    
 
